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Lung cancer, in particular, non-small cell lung cancer (NSCLC), is the leading 
cause of cancer-related deaths in Singapore and worldwide.  CD151 is the first 
member of the transmembrane 4 superfamily of cell-surface proteins identified 
to be a positive effector of tumor cell metastasis.  High expression of CD151 
is associated with poor prognosis for patients with NSCLC.  However, the 
fundamental question that remains largely unanswered is what factor(s) are 
likely to increase its expression.  By identifying factor(s) that influence CD151 
overexpression in NSCLC cells, we can generate potent inhibitors that can 
interrupt this pathway so as to develop novel approaches for lung cancer 
treatment.  We show for the first time that various factors that are associated 
with NSCLC prognosis or progression, in particular, EGF, can upregulate 
CD151 protein expression in not only three NSCLC cell lines, but also in 
colon and breast cancer cell lines.  Importantly, we show that upregulation of 
CD151 is functionally relevant as it is required for EGF-induced cell 
proliferation, possibly via the Akt and ERK1/2 pathways, with a feedback 
inhibitory effect by STAT3 that regulates cyclin D1, pRb and p21 protein 
abundance.  Moreover, CD151 directly affects the protein abundance of pAkt, 
pERK1/2, pSTAT3, cyclin D1, pRb and p21 either basally or in the presence 
of EGF stimulation.  Our study of clinical samples obtained from NSCLC 
patients with wildtype or mutated EGFR shows no correlation between EGFR 
and CD151 expression.  Nonetheless, CD151 is observed to be expressed and 
distributed in a more regulated manner in wildtype EGFR NSCLCs compared 
with mutated EGFR NSCLCs, suggesting a regulatory role of EGFR on 
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CD151, or CD151 on EGFR.  Taken together, our studies support the potential 
of targeting CD151 in the treatment of NSCLC, as well as other cancers where 
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Chapter 1: Introduction 
 
1.1   Lung cancer 
Lung cancer is the leading cause of cancer deaths in men and women worldwide 
(Ferlay et al., 2010).  Based on the GLOBOCAN 2008 estimates, 1.61 million new 
cases of lung cancer (12.7 % of all new cancer cases) and 1.36 million deaths from 
lung cancer (18.2 % of the total cancer deaths) were estimated to have occurred in 
2008.  Lung cancer has the highest incidence (1.1 million cases) and mortality 
(951,000 deaths) in men worldwide and is the fourth most frequent cancer in women.  
Despite a lower incidence (513,000 cases), lung cancer is the second most common 
cause of cancer deaths (427,000 deaths) in women.  The fatality, the ratio of mortality 
to incidence, is 0.86. (Ferlay et al., 2010)  
 
In Singapore, lung cancer is the second and third most frequent cancer in males and 
females, respectively, with a total of 6,407 new cases being diagnosed from 2008-
2012 (Lee et al., 2013).  Consistent with the global cancer statistics by GLOBOCAN 
2008, lung cancer has the highest mortality among the male population and the second 
highest mortality among the female population in Singapore. 3682 lung cancer deaths 
(27.6 % of total) in males and 1842 (16.7 % of total) lung cancer deaths in females 
were reported from 2008-2012.  Of note, the study reported no patients with lung 
cancer that survived more than five years.  





Lung cancer is accompanied by a wide range of symptoms.  Common 
symptoms related to lung function include coughing, bloody sputum, shortness 
of breath, chest pain and hoarseness of voice (Johnston, 2001; Stipp, 2010).  
Other symptoms, such as fatigue, loss of appetite, nausea and weight loss, may 
arise due to the pressure of a tumor on another organ, tumor metastasis or the 
change of hormones in lung cancer patients. 
 
Smoking, particularly cigarette, is by far the leading cause of lung cancer 
which accounts for more than 80 % of lung cancer cases in the United States 
and other countries where cigarette smoking is common (Peto, 1994).  The 
lung cancer risk in smokers is 20-fold higher than never smokers.  Smoking 
cessation can decrease the risk as those who quit smoking are less likely to 
develop lung cancer as compared with those who continue smoking (Khuder 
and Mutgi, 2001).  Other causes which increase the risk of developing lung 
cancer include secondhand cigarette smoking, cigar and pipe smoking, 
occupational exposure to agents such as asbestos and nickel, exposure to radon 
gas, exposure to air pollution and genetics (Alberg et al., 2013). 
 
The international standard for histological classification of lung cancers has 
been proposed by the World Health Organization (WHO) in 2004 (Beasley et 
al., 2005).  Lung cancer can be classified into small cell lung carcinoma 
(SCLC) and non-small cell lung carcinoma (NSCLC) which includes 




adenocarcinoma, squamous cell carcinoma and large cell carcinoma.  Each of 
these can be further classified into more specific subtypes.  This classification 
which is based primarily on the resected specimens has been updated by a new 
lung adenocarcinoma classification published in 2011, under the sponsor of 
the International Association for the Study of Lung Cancer, American 
Thoracic Society, and the European Respiratory Society (IASLC/ATS/ERS), 
which allows the classification of lung cancer in small biopsies and cytology 
(Travis and Rekhtman, 2011).   Unlike the WHO classification whose focus 
has mainly been on the separation of SCLC and NSCLC, this new standard of 
classification has given more attention to the distinction of adenocarcinoma 
and squamous cell carcinoma. 
  
SCLC is categorized as either “limited” or “extensive” disease based on 
whether the tumor is confined to one side of the chest and lymph nodes, or has 
spread to the other part of the chest or metastasized, respectively.  The stages 
of NSCLC, on the other hand, range from I to IV based on the severity of the 
disease.  The lower numbers (I and II) suggest that the tumor is smaller and 
more confined while the higher numbers (III and IV) suggest that the tumor is 
larger or has metastasized. (Edge et al., 2010) 
 
The treatment of lung cancer differs with the histological classification and 
tumor stage (Detterbeck et al., 2013).  Chemotherapy, with or without radiaton 
therapy, is usually given to SCLC patients.  For NSCLC patients in stages I 
and II, surgery, with or without adjuvant chemotherapy, is usually used.  




Radiation therapy, chemotherapy and targeted therapy are given to patients 
with advanced stage lung cancer. 
 
The understanding of the molecular pathology which has advanced 
significantly during the past decade has revolutionalized the lung cancer 
treatment strategies and drug development (Cooper et al., 2013).  A variety of 
oncogenic driver mutations have been identified in lung cancer.  For example, 
KRAS mutations, EGFR mutations and ALK rearrangements are the top most 
frequently detected genetic changes in adenocarcinoma, while TP53 mutations 
have been identified in 64 % of squamous cell carcinoma (Cancer-Genome-
Atlas-Research-Network, 2012; Paik et al., 2011).  Molecular pathology plays 
an increasing role in the diagnosis and management of lung cancer with the 
development of targeted agents.  For instance, the EGFR-tyrosine kinase 
inhibitors (such as gefitinib and erlotinib) which inhibit EGFR functions, 
demonstrate a better response rate and progression-free survival in EGFR 
mutation positive patients over chemotherapy (Maemondo et al., 2010; Mok et 
al., 2009b; Zhou et al., 2011).  
 
1.2   Tetraspanins 
Tetraspanins (transmembrane 4 superfamily proteins, TM4SF) are small, 
membrane-spannning proteins which were first recognized in 1990 (Oren et al., 
1990).  They are 20-30 kDa proteins, between 200-300 amino acids, with a 
variable sequence homology but conserved secondary and tertiary structures 




(Yanez-Mo et al., 2009).  A tetraspanin consists of four transmembrane 
domains, two extracellular loops (a small one and a large one), a small 
intracellular loop connecting the 2
nd
 and the 3
rd
 transmembrane domains, as 
well as short cytoplasmic amino- and carboxyl-termini (Figure 1.1).  The 
small extracellular loop (SEL) has been revealed to pack in under the large 
extracellular loop (LEL) using high-resolution cryoelectron microscopy (Min 
et al., 2006).  The LEL is three to six times larger than the SEL, and can be 
further divided into a conserved and a variable region.  The conserved region 
contains conserved helices, providing a potential dimerization interface; while 




Figure 1.1   Basic structure of a tetraspanin.  Abbreviation: SEL, small 
extracellular loop; LEL, large extracellular loop. 
 





Tetraspanins are found throughout the animal kingdom as well as in lower 
eukaryotes.  Three have been identified in Rhizopus (Lambou et al., 2008), 20 
in Caenorhabditis elegans, 37 in Drosophila melanogaster (Todres et al., 
2000) 47 in bony fish, 32 in mouse and 33 in humans (Huang et al., 2005).  
Tetraspanins are widely expressed in all cell types.  Some tetraspanins such as 
cluster of differentiation 9 (CD9), CD63, CD81, CD82 and CD151 are broadly 
expressed, while others are distributed more specifically in only some cells 
and tissues.  For instance, peripherin/RDS (retinal degeneration slow gene) 
and Rom-1 are expressed only in the photoreceptors (Goldberg, 2006); while 
CD37 are expressed mainly in lymphoid B with very low expression on T 
cells and granulocytes (Schwartz-Albiez et al., 1988).   
 
1.2.1 Functions of tetraspanins 
Tetraspanins are generally located at the plasma membrane.  Distributions in 
lysosomes, endosomes and other intracellular vesicles are also observed in 
some cell types (Escola et al., 1998).  Tetraspanins have been implicated in 
many cellular processes, including cell motility, adhesion, proliferation, 
differentiation and signal transduction (Maecker et al., 1997; Wright and 
Tomlinson, 1994).  They function mainly through their interactions with one 
another, and also with other proteins at the plasma membrane, forming a 
network of interactions called tetraspanin-enriched microdomains (TEMs).  
Sala-Valdes and colleagues have organized the tetraspanin associated proteins 
into five groups (Table 1.1): (1) adhesion molecules, including integrins and 




EpCAM (epithelial cell adhesion molecule); (2) proteins of the Ig superfamily, 
including EW1-2 and CD4; (3) growth factors and their receptors, including 
pro-HB-EGF and EGFR; (4) ectopeptidases and metalloproteinases; and (5) 
intracellular signaling molecules, including PI4K (phosphoinositide 4-kinase) 
and activated PKC (protein kinase C) (Sala-Valdes et al., 2012). 
 
Given the wide distributions and functions of tetraspanins, the dysregulation 
and misfunction have been implicated in several diseases.  CD81 gene 
mutation has been associated with antibody deficiency syndromes, in which 
patients often suffer from recurrent bacterial infections due to the inability to 
respond to antigens (van Zelm et al., 2010).  Defects in TM4SF2 gene which 
is expressed strongly in brain are involved in X-linked mental retardation 
(Abidi et al., 2002; Zemni et al., 2000).  Mutations in TSPAN12, a tetraspanin 
which regulates retinal vascular development (Junge et al., 2009), cause 
autosomal-dominant familial exudative vitreoretinopathy (FEVR), an inherited 
blinding disorder of the retinal vascular system (Poulter et al., 2010).  RDS, 
whose expression is restricted to photoreceptors as stated previously, is 
associated with autosomal dominant retinitis pigmentosa when mutated 
(Kajiwara et al., 1991). 
 




Table 1.1   Tetraspanin associated proteins in TEM [reviewed in (Hemler, 
2003; Sala-Valdes et al., 2012; Stipp, 2010)] 
Group Examples 
Adhesion molecules  Integrins 
 EpCAM (epithelial cell adhesion molecule) 
 VCAM-1 (vascular cell adhesion molecule  1) 








 EWI-F (CD9P-1/FPRP/PTGFRN) 
 EWI-2 (PGRL/CD316/IGSF8) 
 CD2, CD3, CD4, CD8, CD19 
 MHC (major histocompatibility complex) proteins  
- class I MHC 
- class II MHC 
Growth factors and 













 γ-glutamyl transpeptidase 
 pro-MMP-7 




 Heterotrimeric G proteins 
 Type II PI4K (phosphoinositide 4-kinase) 
- PI4KIIA 
- PI4KIIB 
 Classical PKC (protein kinase C) 
- PKCα 
- PKCβ 
 ERM (ezrin-radixin-moesin) family proteins 




 AP adaptor proteins 








1.3   CD151 
CD151, also known as PETA-3 (platelet-endothelial cell tetraspanin antigen 3), 
SFA-1 (SF-HT activated gene 1) or TSPAN24, is one of the 33 members of 
human TM4SF superfamily.  CD151 gene is located on chromosome 11p15.5 
(Hasegawa et al., 1997).  It was first identified as a 27 kDa platelet surface 
glycoprotein using a monoclonal antibody raised against acute myeloid 
leukemia (AML) cells (Ashman et al., 1991).  Similar to other tetraspanins, 
CD151 consists of four transmembrane domains, two extracellular loops, a 
small intracellular loop and two short cytoplasmic NH2- and COOH-terminal 
tails (Fitter et al., 1995).  It is widely expressed by endothelium, epithelium, 
Schwann cells, dendritic cells and muscles (Sincock et al., 1997).   
 
1.3.1 Functions of CD151 
CD151 has been shown to associate strongly with laminin-binding integrins 
α3β1, α6β1 and α6β4 (Lammerding et al., 2003; Tran et al., 2007; Yauch et al., 
1998).  It regulates integrin-ligand interaction, integrin-triggered signaling, 
intracellular integrin trafficking and recycling, and the compartmentalization 
of integrin on the cell surface (Berditchevski, 2001).  With these regulatory 
functions on integrins, CD151 is involved in integrin-mediated cellular 
processes such as cell adhesion and motility.  In the TEMs on plasma 
membrane, CD151 acts as a molecular linker between different tetraspanins, 
integrins, other transmembrane proteins and signaling molecules.  It mediates 
the functions of several growth factors such as epidermal growth factor (EGF), 
c-Met and transforming growth factor-beta (TGF-β) (Franco et al., 2010; Sadej 




et al., 2010; Yang et al., 2008).  Some of the adhesion-dependent signaling 
enzymes recruited by CD151 into integrin complexes include PI4K and PKC 
(Yauch et al., 1998; Zhang et al., 2001).  In addition, it regulates epithelial 
cell-cell contact by modulating PKC, Cdc42, cadherin-catenin and RhoA-
dependent actin cytoskeletal reorganization (Chattopadhyay et al., 2003; 
Johnson et al., 2009; Shigeta et al., 2003). 
 
Patients with CD151 mutations suffer from hereditary nephritis, sensorineural 
deafness, pretebial epidermolysis bullosa, and β-thalasemia minor (Karamatic 
Crew et al., 2004).  CD151 forms very stable complexes with integrins α3β1 
and α6β1 in kidney, and α3β1 and α6β4 in skin.  The abnormalities in the 
patients with CD151 mutations may result from the impaired function of 
CD151 to maintain the integrity of basement membranes in the patients’ 
kidney, skin and inner ear; and the improper regulation of erythropoiesis of the 
patients. 
 
The phenotypes of CD151 knockout mice vary with the genetic backgrounds 
of the mice.  CD151-null C57BL/6 mice show normal blood and bone marrow 
cell counts and grossly normal tissue morphology, but exhibit minor 
abnormality in hemostasis - with longer average bleeding time, greater 
average blood loss and increased rebleeding occurrences (Wright et al., 2004).   
CD151 knockout mice with FVB/N background are normal and healthy at 
birth, but develop kidney failure with age (Sachs et al., 2006).  Of note, neither 




skin abnormality nor hearing disability observed in CD151 mutated patients 
are developed in these CD151-null mice. 
 
1.3.2 CD151 in cancer 
CD151 is the first tetraspanin member to be linked as a positive effector of 
metastasis.  Tesla and colleagues found that a monoclonal antibody targeting 
against CD151 specifically inhibited metastasis (Testa et al., 1999).  
Subsequent studies have shown elevated CD151 expression in various 
malignant tumors such as breast, colon, prostate cancers and NSCLC, as 
compared to healthy tissues (Ang et al., 2004; Hashida et al., 2003; Kwon et 
al., 2013; Sadej et al., 2009).  CD151 overexpression is correlated with the 
poor prognosis (lower survival and/or higher recurrence rate) of these cancers.  
In addition, CD151 has been shown to be a better prognostic indicator in 
patients with prostate cancer than the traditional histological grading method 
(Ang et al., 2004).   
 
Figure 1.2 summarizes the contributions of CD151 in cancer progression.  
The functions of CD151 on integrins are important in tumor progression.  The 
association of CD151 with integrin α6β4 correlates with increased tumor cell 
motility (Gesierich et al., 2005).  It regulates the molecular organization and 
functions of integrin α6 to accelerate breast cancer progression (Yang et al., 
2008).  The association between CD151 with integrin regulates carcinoma-
stroma interaction.  The co-internalization of integrin α3β1 with CD151 




enhanced EGF-stimulated cell migration and invasion (Hasegawa et al., 2007).  
Consistent with this, integrin trafficking is affected in the absence of CD151, 
leading to impaired cell motility and cell adhesion (Winterwood et al., 2006).  
CD151, with integrin, modulates the interactions of tumor cells with the 
stroma and endothelium to promote tumorigenesis (Sadej et al., 2009; Takeda 
et al., 2011).  CD151 also stabilizes carcinoma cell-cell contacts, which is 
important for the metastasis of carcinomas, through its interaction with 
integrin α3β1 (Johnson et al., 2009). 
 
CD151 has a role in the growth factor-mediated interplay between tumor and 
its microenvironment which is important for tumor cell growth and survival.  
The presence of CD151 on cell membranes regulates growth factor receptor 
function and its response to the stimuli generated by the stroma (Sadej et al., 
2014).  CD151 forms functional complex with c-Met, hepatocyte growth 
factor (HGF) receptor, and mediates HGF-induced signaling and oncogenic 
events such as tumor cell morphogenesis and tumor cell growth (Franco et al., 
2010; Klosek et al., 2009; Klosek et al., 2005).  CD151 potentiates TGF-β1 
responses, enhancing tumor cell proliferation and facilitating local 
invasiveness (Sadej et al., 2010).  Its silencing is found to attenuate TGF-β1 
signaling, leading to reduced tumor cell retention in the lung vascular bed, 
inhibited the pneumocyte-induced cell scattering and decreased pulmonary 
metastasis of the cancer cells (Sadej et al., 2010).  CD151 regulates EGF-
induced cell migration, invasion and spreading by mediating the interaction 
between EGFR and integrin α6 (Yang et al., 2008). 





CD151 also mediates processes contributing to tumor metastasis, such as 
epithelial-mesenchymal transition (EMT), matrix metalloproteinases (MMP) 
activation and angiogenesis.  CD151 induces EMT and cell spreading in breast 
cancer cells (Ke et al., 2011).  It upregulates and activates MMPs such as 
MMP7 and MMP9, and strengthens cell adhesions to the extracellular matrix 
(ECM) (Hasegawa et al., 2007; Shiomi et al., 2005).  CD151 further 
contributes to metastasis by regulating angiogenesis, and the intravasation of 
tumor cells to the vascular system (Takeda et al., 2007; Zijlstra et al., 2008).  
 
Figure 1.2   Contributions of CD151 in cancer progression.  Abbreviations: 
EMT, epithelial-mesenchymal transition; HGFR, hepatocyte growth factor 
receptor; EGFR, epidermal growth factor receptor; TGF-β1R, transforming 
growth factor-beta 1 receptor; MMP, matrix metalloproteinase; ECM, 
extracellular matrix. 
 




1.4   Regulatory factors in lung cancer 
Cancer occurs when the network of regulatory circuitry within cells is 
disturbed, leading to the multistep development of human tumors.  The 
hallmarks of cancer comprise of eight biological capabilities: sustaining 
proliferative signaling, evading growth suppressors, resisting cell death, 
enabling replicative immortality, inducing angiogenesis, activating invasion 
and metastasis, reprogramming of energy metabolism, and evading immune 
destruction (Hanahan and Weinberg, 2011).  Several regulatory factors, whose 
aberrant signaling leads to lung cancer development, are discussed below. 
 
1.4.1 Pro-inflammatory cytokines 
Pro-inflammatory cytokines are cytokines that promote inflammation 
(Dinarello, 2000).  They are overexpressed in various cancers including 
NSCLC (Candido and Hagemann, 2013).  Dysregulation of the immune 
response components such as pro-inflammatory cytokines induces the 
initiation and progression of cancer by causing chronic inflammation and 
generating microenvironment that favors tumor growth (Mantovani et al., 
2008).  In addition, these inflammatory mediators induce DNA damage in 
tumor suppressor genes and modulate cellular processes such as apoptosis, 
DNA repair and cell cycle checkpoints (Morrison, 2012).  In our study, we 
have chosen to focus on two pro-inflammatory cytokines, TNF-α and IL-1β. 
 
 




Tumor necrosis factor alpha (TNF-α) 
TNF-α is a pro-inflammatory cytokine that promotes inflammatory responses, 
autoimmune, and malignant diseases (Bazzoni and Beutler, 1996; Beutler and 
Bazzoni, 1998).  The plasma level of TNF-α is elevated in NSCLC patients 
compared with controls (Kumar et al., 2010).  Wang and colleagues showed 
that the serum TNF-α level of NSCLC patients is significantly associated with 
their smoking status (Wang et al., 2013).  In the same study, they showed that 
patients with high expression of the serum TNF-α have a shorter time to 
progression and overall survival.  Interestingly, TNF-α promoter 
polymorphisms are correlated with the susceptibility to, and the severity of 
NSCLC (Shih et al., 2006).  The frequency of TNF-α-308 A allele, which 
accounts for an increased TNF-α production, is significantly higher in lung 
cancer patients compared with controls (thereby promoting lung cancer 
development) while the TNF-α-238 A allele, which accounts for decreased 
TNF-α production, has an opposite effect (Shih et al., 2006). 
 
Interleukin-1 beta (IL-1β) 
IL-1β is a major mediator of both acute and chronic inflammation (Bird et al., 
2002).  It promotes tumor progression by inducing either angiogenic or 
inflammatory pathways (Saijo et al., 2002; Salven et al., 2002).  It is highly 
expressed by metastatic NSCLC tumors, contributing to angiogenesis and 
tumor growth (Elaraj et al., 2006).  Similar to TNF-α, a number of studies 
have correlated IL-1β gene polymorphisms with the risk of NSCLC (Landvik 
et al., 2009; Wu et al., 2010; Zienolddiny et al., 2004).  The promoter IL-1β-




511 T allele and -31 C allele are over represented in lung cancer patients 
compared with healthy controls (Zienolddiny et al., 2004).  In addition, a 
specific haplotype, formed by IL-1β-3893 G, -1464 G, -511 C and -31 T, 
which is associated with an increased expression of IL-1β gene, is found to 
increase NSCLC risk (Landvik et al., 2009). 
 
1.4.2 G protein-coupled receptor (GPCR) activators 
GPCRs constitute the largest family of cell surface molecules which can sense 
a wide variety of extracellular stimuli, regulating biological processes such as 
synaptic neurotransmission, immune response, cell growth and differentiation 
(Lefkowitz, 2000).  Diverse GPCRs are overexpressed in primary and 
metastatic tumor cells, including NSCLC (Li et al., 2005).  Aberrant GPCRs 
and their ligands cause cancer by mediating tumorigenesis, angiogenesis and 
metastasis (Wu et al., 2012).  In our study, we have focused on two GPCRs, 
histamine and nicotine. 
 
Histamine 
Histamine is a critical regulator of the innate and adaptive immune responses 
(O'Mahony et al., 2011).  A higher histamine concentration is observed in 
melanomas, colon and breast tumors compared with the surrounding normal 
tissues; and it mediates cancer development and progression (Medina and 
Rivera, 2010).  Nonetheless, the correlation between histamine expression and 
NSCLC prognosis remains unknown.  Although the plasma histamine level in 




lung cancer patients is detected to be lower than the healthy controls (Della 
Rovere et al., 2006), it has been shown to be synthesized, stored and released 
by cultured SCLC cells (Graff et al., 2002).  Stoyanov and colleagues 
demonstrated that histamine enhanced NSCLC cell proliferation (Stoyanov et 
al., 2012).  In addition, a higher cumulative use of histamine-2-receptor 
blockers is associated with a reduced risk of NSCLC (Hsu et al., 2013), 
supporting the pathological role of histamine in NSCLC. 
 
Nicotine 
Nicotine is the principal psychoactive component in tobacco that causes 
addiction to smoke and high incidence of relapse among smoke quitters.  It 
exerts its effects on the central nervous system by interacting with nicotine 
acetylcholine receptors (nAChR) (Laviolette and van der Kooy, 2004).  
Although nicotine itself is not a carcinogen that induces lung cancer, different 
studies established that nicotine induces proliferation and inhibits drug-
induced apoptosis of lung cancer cells (Dasgupta et al., 2006; Zhang et al., 
2006).  It stimulates angiogenesis and promotes tumor growth in cancer 
xenograft models (Heeschen et al., 2001).  Interestingly, the polymorphisms of 
nAChR subunits (CHRNA5, CHRNA3 and CHRNB4) have been shown to be 
associated with lung cancer risk in a number of studies.  For example, 
rs1051730 (a SNP in CHRNA3 gene) and rs16969968 (a SNP in CHRNA5 
gene) are associated with high risk of lung cancer in Caucasians as well as 
Japanese; rs3743073 (a SNP in CHRNA3 gene) is associated with increased 
lung cancer risk and poor survival in advanced stage NSCLC patients of 




Chinese Han populations (Hung et al., 2008; Niu et al., 2010; Shiraishi et al., 
2009).  
 
1.4.3 Growth factors 
Growth factors are polypeptides that stimulate cell proliferation.  
Nontransformed cells require more than one growth factor for cell 
proliferation and this process is tightly regulated (Goustin et al., 1986).  
Aberrations in growth factor signaling, causing extensive growth of the 
transformed cells, are associated with cancer development.  Defect in growth 
factor regulation and the switch from a paracrine to an autocrine mechanism of 
action give rise to malignancy.  Besides stimulating cell proliferation, some 
growth factors induce tumor growth by promoting tumor vascularisation. 
(Favoni and de Cupis, 2000)  In our study, we have focused on three growth 
factors, TGF-β1, VEGF and EGF. 
 
Transforming growth factor-beta 1 (TGF-β1) 
TGF-β1 is a multifunctional cytokine which controls cell growth and 
differentiation, induces fibrosis and scar formation, suppresses immune 
response, stimulates angiogenesis, promote tumor development and regulates 
inflammatory processes (Kajdaniuk et al., 2013).  The plasma levels of TGF-
β1 are higher in NSCLC patients compared with controls (Kumar et al., 2010).  
A high level of TGF-β1 is significantly correlated with a higher density of 
microvessels in NSCLC tumors, and may thus affect the tumor angiogenesis 




and promote tumor progression in NSCLC patients.  Moreover, the increase in 
TGF-β1 protein level is correlated with lymph node metastasis, and advanced 
stages of NSCLC disease progression.  In lung adenocarcinoma, a significant 
correlation between the TGF-β1 level and disease prognosis is observed 
(Hasegawa et al., 2001).  Its level may be used as an independent predictor of 
survival in patients with lung adenocarcinoma. 
 
Vascular endothelial growth factor (VEGF) 
VEGF is the most important angiogenic factor which regulates both 
physiological and pathological angiogene (Veikkola and Alitalo, 1999).  The 
serum VEGF level is higher in NSCLC patients as compared to healthy 
controls, and elevated tumor VEGF level is observed in more than 40 % of 
NSCLC patients (Fleitas et al., 2013; O'Byrne et al., 2000; Song et al., 2013).  
The VEGF level is also higher in patients with advanced disease stages 
compared with early stages, and in smokers compared with non-smokers 
(Song et al., 2013).  Evidently, there is a positive correlation between VEGF 
level and the tumor microvessel density, an indication of tumor angiogenesis 
(Farhat et al., 2012).  High levels of tumor and circulating VEGF are 









Epidermal growth factor (EGF) 
EGF is a specific ligand of EGFR.  Aberrant EGFR signaling contributes to 
lung cancer development and progression; while overexpression and activating 
mutations of EGFR are associated with the poor prognosis of lung cancer 
(discussed further in Section 1.5 below).  
 
1.5   EGF and EGFR 
The epidermal growth factor receptor (EGFR) family, also known as the HER 
or ErbB family, is a member of the subclass I of the transmembrane receptor 
tyrosine kinase (RTK) superfamily.  It consists of four known closely related 
members: EGFR/ErbB1/Her1, ErbB2/Her2, ErbB3/Her3 and ErbB4/Her4.  
They are expressed in various tissues of epithelial, mesenchymal and neuronal 
origin. (Hynes and Lane, 2005)  EGFR is a 170 kDa transmembrane 
glycoprotein whose gene is located in the 7p12 region of chromosome 7 
(Wang et al., 1993).  Structurally, EGFR is comprised of an extracellular 
region, a single transmembrane helix region and a cytoplasmic region.  The 
extracellular region constitutes the input layer where ligand binding takes 
place and signals are received, the transmembrane region is the signal 
processing layer where dimerization occurs, while the tyrosine kinase 
containing intracellular region is the output layer which leads to the 
downstream signaling upon activation (Wujcik, 2006).  Besides the tyrosine 
kinase domain (which accounts for about 50 % of the total region), the 
cytoplasmic region consists of 38 amino acid cytoplasmic juxtamembrane 
region and 225 amino acid carboxyl terminal (Red Brewer et al., 2009). 





EGF belongs to the EGF-family of ligands which are divided into three groups; 
each binds speficically to the ErbB receptors.  The first group includes EGF, 
TGF-α, amphiregulin and epigen which bind specifically to EGFR.  The 
second group includes betacellulin, heparin-binding EGF and epiregulin which 
bind to both EGFR and ErbB4.  The third group includes neuregulin-1 and 
neuregulin-2 which bind to both ErbB3 and ErbB4, as well as neuregulin-3 
and neuregulin-4 which bind to ErbB4 only. (Hynes and MacDonald, 2009)  
None of the ligands bind to ErbB2.  With the open conformation which makes 
it the preferred dimerization partner for all the other ErbB receptors, ErbB2 is 
activated via the heterodimerization with the other ligand-bound receptors 
(Graus-Porta et al., 1997). 
 
1.5.1 EGFR signaling 
Upon ligand binding to the extracellular domain of a monomeric EGFR, the 
conformational changes in EGFR allow for the formation of either 
homodimers or heterodimers with other ErbB receptors.  Autophosphorylation 
on the tyrosine residues of the receptors occur and the phosphorylated receptor 
dimers serve as docking sites for various adaptor proteins or enzymes, 
mediating downstream signaling cascades. (Yarden and Sliwkowski, 2001)  
With these, EGFR induces various cellular functions such as proliferation, 
differentiation, migration and survival (Cheng et al., 2011). 
 




MAPK (mitogen-activated protein kinase) or ERK (extracellular signal-
regulated kinase), PI3K (phosphoinositide 3-kinase)-Akt and STAT (signal 
transducers and activators of transcription) pathways are three main 
downstream pathways of EGFR (Gazdar, 2010) (Figure 1.3).  When EGFR is 
activated, ERK1/2 are phosphorylated and translocate to the nucleus, 
promoting cell growth, differentiation and mitosis by transactivating 
transcription factors (Zhang and Liu, 2002).   PI3K, on the other hand, is 
recruited to the membrane upon EGFR activation.  The activated PI3K 
produces phosphatidylinositol-3,4,5-triphosphate (PIP3) which recruits 
signaling molecules such as Akt.  Phosphorylated Akt promotes cellular 
survival, growth and proliferation by mediating the activation and inhibition of 
several targets such as mTOR (mammalian target of rapamycin) and Bad. 
(Fresno Vara et al., 2004)  STATs translocate to the nucleus to mediate cell 
proliferation, differentiation, migration and apoptosis by stimulating the 
transcription of nuclear factors upon activation by phosphorylation (Johnson et 
al., 2012). 
 








1.5.2 EGFR in cancer 
Given the importance of EGFR in various physiological functions, the 
abnormalities in EGFR signaling lead to downstream events that stimulate the 
hallmarks of cancer.  These include the evasion of apoptosis, self-sufficient 
growth, insensitivity to anti-growth signals, sustained angiogenesis, and tissue 
invasion and metastasis (Gazdar, 2010).  Several events can lead to aberrations 
in EGFR signaling.  Some of them include the trigger of intracellular signals 
by the EGFR receptor pairs without the activation by a growth factor; 
mutations of receptors which are constitutively active; as well as the autocrine 
Figure 1.3   EGFR signaling.  Abbreviation: EGF, epidermal growth factor; EGFR, 
epidermal growth factor receptor; ERK1/2, extracellular signal-regulated kinase 1/2; 
STATs, signal transducers and activators of transcription; PI3K, phosphoinositide 3-
kinase. 




response by the ligands and receptors produced by cells (Ennis et al., 1991).  
The aberrant signaling contributes to the development and progress of cancers 
by initiating the downstream mitogen events as stated above (i.e. MAPK, 
PI3K/Akt and STAT signaling pathways). 
 
EGFR is overexpressed in a variety of human cancers, such as lung, head and 
neck, colon and breast (Grandis and Tweardy, 1993; Rusch et al., 1997; Spano 
et al., 2005; Tsutsui et al., 2002).  Its overexpression is observed in more than 
60 % of NSCLCs, but not in SCLC, and is correlated with the poor prognosis 
of the disease (Hirsch et al., 2003; Ohsaki et al., 2000).   Mutations in EGFR 
are also frequently detected in NSCLCs.  Deletion mutation in the EGFR 
extracellular region, associated with constitutive activation, is detected in 5 % 
of lung squamous cell carcinoma (Ji et al., 2006).  In the intracellular region, 
deletions of exon 19 and a point mutation (L858R) in exon 21 account for 
more than 90 % of all EGFR kinase mutations in NSCLCs, while point 
mutations in exon 18 and exon 20 account for around 5 % each (Zhang et al., 
2010).  EGFR has evolved as an important target of individualized therapy for 
NSCLC treatment.  A monoclonal antibody preventing ligand binding to the 
extracellular domain (such as cetuxumab) and a small molecule inhibiting the 
intracellular tyrosine kinase activity, the tyrosine kinase inhibitor TKI, (such 
as gefitinib and erlotinib) are two major approaches to inhibit EGFR signaling 
clinically, exhibiting promising therapeutic potential (Cheng et al., 2011; 
Wujcik, 2006).  For instance, the use of EGFR-TKI has successfully increased 
the response rates and prolonged the progression-free survival in NSCLC 
patients with EGFR mutations. 





1.6   Objectives and aims of the study 
CD151 is overexpressed in more than 25 % of NSCLCs and the high 
expression is correlated with reduced overall and disease-free survival (Kwon 
et al., 2013).  Despite the recognition of the clinical significance and 
contributions of CD151 in cancers as mentioned above, the fundamental 
question that remains largely unanswered is what factor(s) are likely to 
increase the expression of CD151.  Therefore, using A549 cells (a NSCLC cell 
line) as our study model, the first aim of our study is to identify potential 
factor(s) that can upregulate CD151 expression in cancers.  The second aim is 
to determine the role of CD151 in the tumor progression induced by the factor 
identified in the first aim, and subsequently to investigate the mechanisms 
involved in the process.  By identifying factor(s) that influence CD151 
overexpression in NSCLC cells and the mechanistic role of CD151 in the 
factor-induced cancer progression, this study can provide a basis for future 
work to generate potent inhibitors that can interrupt this pathway so as to 




Chapter 2: Methods 
 
2.1   Preparation of cell culture media, buffers and chemicals 
 
2.1.1 Preparation of cell culture media 
DMEM, high glucose, no glutamine, no phenol red (Catalogue number: 
31053-028) was purchased from Life Technologies (USA).  10 ml of 200 mM 
(100X) L-glutamine (final concentration, 4 mM, Life Technologies, USA) and 
5 ml of 100 mM sodium pyruvate (final concentration, 1 mM, Sigma, USA) 
were added to the 500 ml medium, and the solution was stored at 4 ⁰C until 
required. 
RPMI-1640 medium, no phenol red (Catalogue number: 11835-030) was 
purchased from Life Technologies (USA).  5 ml of 100 mM sodium pyruvate 
(final concentration, 1 mM) was added to the 500 ml medium, and the solution 
was stored at 4 ⁰C until required. 
 
2.1.2 Preparation of magnesium chloride (MgCl2) 
2.3 g of MgCl2 (final concentration, 1 M, Merck, Germany) was dissolved in 
10 ml of Milli-Q water.  The solution was stored at room temperature until 
required. 
 




2.1.3 Preparation of aprotinin 
5 mg of aprotinin (final concentration, 1 mg/ml, Sigma, USA) was added to 5 
ml of GIBCO water (Invitrogen, USA).  The solution was mixed by vortexing 
gently and kept on ice for 5 min to fully dissolve.  Small aliquots were made 
and stored at -20 ⁰C until required. 
 
2.1.4 Preparation of sodium orthovanadate (Na3VO4) 
1.84 g of Na3VO4 (final concentration, 200 mM, Sigma, USA) was dissolved 
in 38 ml of Milli-Q water, adjusted to pH 10 using concentrated HCl and 
boiled for 3 min (pH ~9).  1.25 ml of NaOH was then added.  The solution 
was boiled for 3 min and adjusted to pH 10 again.  The processes of boiling 
and pH adjusting to 10 were repeated until the solution remained colorless and 
the pH stabilized at 10.  The solution was topped up to 50 ml with Milli-Q 
water.  Small aliquots were made and stored at -20 ⁰C until required. 
 
2.1.5 Preparation of phenylmethylsulphonyl fluoride (PMSF) 
174 mg of PMSF (final concentration, 200 mM, Sigma, USA) was dissolved 
in 5ml of 100 % ethanol (Merck, Germany).  Small aliquots were made and 
stored at -20 ⁰C until required.  PMSF is unstable in aqueous solution (half life, 
~30 min) and therefore was only added to the lysis buffer just prior to use. 
 
 




2.1.6 Preparation of cell lysis buffer 
To prepare lysis buffer stock, 0.186 g of EDTA (final concentration, 2 mM, 
Bio-Rad Laboratories, USA) was dissolved in 100 ml of Milli-Q water (resin 
filtered and deionised) and adjusted to pH 7.5 using 5 N HCl.  1.46 g of NaCl 
(final concentration, 100 mM, Merck, Germany) and 0.304 g of Tris-Base 
(final concentration, 10 mM, Sigma, USA) were then added into the solution.  
The pH of the mixture was adjusted to 7.5 using 1 M NaOH.  In another 100 
ml of Milli-Q water, 2.5 ml of Triton X-100 (final concentration, 1 % v/v, 
Merck, Germany) was added and dissolved, followed by an addition of 1.25 g 
of deoxycholate (final concentration, 0.5 % w/v, Sigma, USA) without 
agitation.  After the reagents were dissolved, the solution was combined with 
the previous 100 ml of solution and kept at 4 ⁰C until required. 
For every ml of lysis buffer stock, 10 µl of MgCl2 (final concentration, 10 
mM), 1 µl of aprotinin (final concentration, 1 µg/ml), 0.5 µl of Na3VO4 (final 
concentration, 100 µM) and 5 ml of PMSF (final concentration, 1 mM) were 
freshly added prior to use. 
 
2.1.7 Preparation of 1.5 M Tris-HCl pH 8.8 
54.51 g of Tris-Base was dissolved in 150 ml of Milli-Q water and adjusted to 
pH 8.8 using 5 N HCl.  The solution was topped up to 300 ml with Milli-Q 
water and stored at room temperature until required. 
 
 




2.1.8 Preparation of 1.0 M Tris-HCl pH 6.8 
12.11 g of Tris-Base was dissolved in 60 ml of Milli-Q water and adjusted to 
pH 6.8 using 5 N HCl.  The solution was topped up to 100 ml with Milli-Q 
water and stored at room temperature until required. 
 
2.1.9 Preparation of ammonium persulphate (APS) 
0.1 g of APS (final concentration, 10 % w/v, Sigma, USA) was dissolved in 
1ml of Milli-Q water and stored in dark at room temperature until required, for 
up to 1 week. 
 
2.1.10   Preparation of 8 % resolving gel 
To make 15 ml of 8 % resolving gel solution, 4 ml of 30 % acrylamide mix 
(Bio-Rad Laboratories, USA), 3.8 ml of 1.5 M Tris-HCl pH 8.8 and 150 µl of 
10 % SDS were mixed with 6.9 ml of Milli-Q water.  150 µl of 10 % APS and 
9 µl of N,N,N,N-tetramethylethylenediamine (TEMED, Sigma, USA) were 
added to the solution just prior to casting the resolving gels.  The gels were left 
to solidify at room temperature for 1-1.5 h, before the staking gels were casted. 
 
2.1.11   Preparation of 12 % resolving gel 
To make 15 ml of 12 % resolving gel solution, 6 ml of 30 % acrylamide mix, 
3.8 ml of 1.5 M Tris-HCl pH 8.8 and 150 µl of 10 % SDS were mixed with 
4.9 ml of Milli-Q water.  150 µl of 10 % APS and 6 µl of TEMED were added 




to the solution just prior to casting the resolving gels.  The gels were left to 
solidify at room temperature for 1-1.5 h, before the stacking gels were casted. 
 
2.1.12   Preparation of 5 % stacking gel  
To make 8 ml of 5 % stacking gel solution, 1.3 ml of 30 % acrylamide mix, 1 
ml of 1.0 M Tris-HCl pH 6.8 and 80 µl of 10 % SDS were mixed with 5.5 ml 
of Milli-Q water.  80 µl of 10 % APS and 8 µl of TEMED were added to the 
solution just prior to casting the stacking gels.  The gels were left to solidify at 
room temperature for at least 30 min before being kept at 4 ⁰C until required 
for Western blot analysis, for up to 3 days. 
 
2.1.13 Preparation of sample buffer for Western blotting 
7 ml of 1 M Tris-HCl pH 6.8 (final concentration, 0.175 M), 2.05 g of SDS 
powder (final concentration, 5.14 % w/v), 7.2 ml glycerol (final concentration, 
18 % v/v, Sigma, USA) and 0.003 g of bromophenol blue (final concentration, 
0.006 % w/v, Sigma, USA) were mixed and the solution were kept at room 
temperature until required. 
For antibody that required a reducing condition, 2.1 µl of β-mercaptoethanol 








2.1.14 Preparation of running buffer 
30.3 g of Tris-Base (final concentration in 1X running buffer, 25 mM), 144 g 
of glycine (final concentration in 1X running buffer, 192 mM, Sigma, USA) 
and 100 ml of 10 % SDS (final concentration in 1X running buffer, 0.1 % v/v, 
1
st
 Base, Singapore) were added into 800 ml of Milli-Q water.  After the 
reagents were dissolved, the solution was topped up to 1 L with Milli-Q water 
to make a 10X stock.  The pH was not adjusted and should be 8.3 when 
diluted to 1X.  The stock was stored at 4 ⁰C until required, for up to one month.   
To prepare 1 L of 1X running buffer, 100 ml of the 10X stock was added to 
900 ml of Milli-Q water.  The pH was checked prior to use.  If the pH was not 
8.3, new 10X stock was made. 
 
2.1.15 Preparation of transfer buffer 
30.3 g of Tris-Base (final concentration in 1X transfer buffer, 25 mM) and 150 
g of glycine (final concentration in 1X transfer buffer, 200 mM) were 
dissolved in 1 L of Milli-Q water to make a 10X stock.  The solution was 
stored at 4 ⁰C until required. 
To prepare 1 L of 1X running buffer, 100 ml of the 10X stock was diluted in 
700 ml of Milli-Q water.  200 ml of 100 % methanol (final concentration, 20 % 
v/v, Fisher Scientific, UK) and 4 ml of 10 % SDS (final concentration, 0.04 % 
v/v) were then added.  The pH was checked prior to use.  If the pH was not 8.3, 
new 10X stock was made. 
 




2.1.16 Preparation of Tris-buffered saline (TBS) 
24.2 g of Tris-Base (final concentration in 1X TBS, 20 mM) and 80 g of NaCl 
(final concentration in 1X TBS, 137 mM, Merck, Germany) were dissolved in 
800 ml of Milli-Q water and adjusted to pH 7.0 using 5 M HCl.  The solution 
was topped up to 1 L with Milli-Q water to make a 10X stock and stored at 
room temperature until required. 
To make 1 L of TBS-Tween 0.1 %, 100 ml of the 10X stock was diluted in 
900 ml of Milli-Q water.  1 ml of Tween 20 (final concentration, 0.1 % v/v, 
Sigma, USA) was then added. 
 
2.1.17 Preparation of Tris-EDTA (pH 9) buffer 
1.21 g of Tris-Base and 0.372 g of EDTA were added to 900 ml of Milli-Q 
water.  The solution was adjusted to pH 9.0 and topped up to 1 L with Milli-Q 
water.  The solution was then stored at room temperature until required. 
 
2.2   Cell culture 
Normal lung epithelial BEAS-2B cells, non-small cell lung carcinoma A549, 
H358, H1975 and SK-MES-1 cells, colon cancer SW620 cells and breast 
cancer MDA-MB-231 cells were from American Type Culture Collection 
(ATCC, USA).  BEAS-2B, A549 and SW620 cells were cultured in phenol 
red free Dulbecco’s Modified Eagle Medium (DMEM, Life Technologies, 
USA), SK-MES-1 cells were cultured in Eagle’s Minimum Essential Medium 




(EMEM, ATCC, USA), while H358, H1975 and MDA-MB-231 cells were 
cultured in phenol red free Roswell Park Memorial Institute (RPMI)-1640 
Medium (Life Technologies, USA), at 37 °C under 5 % CO2 and 95 % air.  All 
complete culture media were supplemented with 10 % fetal bovine serum 
(FBS, Invitrogen, USA) and 1 % penicillin-streptomycin (P/S, Life 
Technologies, USA). 
 
2.3   Cell stimulation 
20,000 cells were plated onto 6-well plates in complete cell culture media.  
After 48 h, the culture media was switched to incomplete media, containing 1 % 
P/S and 0.5 % FBS for 24 h, allowing for cell cycle synchronization prior to 
stimulation with different concentrations of EGF (Sigma, USA), TGF-β1 
(R&D System, USA), VEGF 165 (R&D Systems, USA), TNF-α (PeptroTech, 
USA), IL-1β (Sigma, USA), histamine (Sigma, USA) or nicotine (Sigma, 
USA).  Cells were lysed for Western blot analysis after 48 h of stimulation. 
 
2.4   Gene silencing by small interfering RNA (siRNA) 
siRNA transfection was carried out when culture media was switched to 
incomplete media.  Two commercially available siRNA kits were used.  The 
first was purchased from Dharmacon (USA) whereby the CD151-specific-
siRNA smartpool, which contained the target sequences 
GAUCAUCGCUGGUAUCCUC, GCAAGACGGUGGUGGCUCU, 
CCUCAAGAGUGACUACAUC and UCACAGGACUGGCGAGACA were 




used.  Cells were transfected with 12.5 nM siRNA using 1 µl/well of 
DharmaFECT1 according to the manufacturer’s protocol.  The vehicle control 
contained only the DharmaFECT1 Transfection Reagent, while ON-
TARGETplus Non-targeting siRNA#1 (Dharmacon, USA) was used as a 
negative control.  Knockdown efficiency was 85 %, as determined by Western 
blot analysis (Figure 3.5A). 
The second commercially available siRNA for CD151 was from Qiagen 
(USA); 5 nM of the CD151 FlexiTube siRNA6 was transfected into the cells 
using 6 µl of HiPerFect Transfection Reagent (Qiagen, USA) according to the 
manufacturer’s protocol.  The vehicle control contained only the HiPerFect 
Transfection Reagent, while ON-TARGETplus Non-targeting siRNA#3 
(Dharmacon, USA) was used as a negative control.  Knockdown efficiency 
was 85 %, as determined by Western blot analysis (Figure 3.5B). 
Cells were stimulated with 10 ng/ml of EGF either 24 h after siRNA 
transfection for cell counting by trypan blue exclusion or 48 h after siRNA 
transfection for signaling experiments. 
 
2.5   Generation of pEGFP-CD151 cell lines 
pEGFP-CD151 and pEGFP-N3 vectors were kind gifts from Professor 
Kiyotoshi Sekiguchi (Osaka University, Japan).  The CD151 gene insert was 
verified using HindIII and NotI (New England Biolabs, UK) restriction 
enzyme digestion to release the 1.47 kbp CD151-GFP fragment.  A geneticin 
(Life Technologies, USA) killing curve for A549 cells was generated using 




0.3 µg/µl, 0.6 µg/µl, 1.0 µg/µl and 1.2 µg/µl of geneticin in complete DMEM.  
1.2 µg/µl was observed to cause excessive A549 cell death at day 14, thus 
being selected as the killing concentration; while 0.6 µg/µl was chosen as the 
maintenance concentration for the stable cell lines. 
5 µg of pEGFP-N3 and pEGFP-CD151 vectors were transfected into A549 
cells seeded on 100 mm dish, using 20 µl of Lipofectamine LTX (Invitrogen, 
USA) and 5 µl of PLUS reagent (Invitrogen, USA), according to the 
manufacturer’s protocol.  After two days, the culture media were switched to 
complete media containing 1.2 µg/µl of geneticin and allowed to grow for 
another 14 days.  As a control, non-transfected A549 cells were also incubated 
with 1.2 µg/µl of geneticin and were observed with excessive cell death at day 
14.  Consequently, single colonies on the transfected plates (surviving cells 
stably overexpressing the plasmids and acquired the resistance against 
geneticin) were picked and cultured in 100 µl of complete media containing 
0.6 µg/µl of geneticin in a 96-well format.  After 10 days, cells with GFP 
fluorescence, as viewed under a fluorescence microscope, were trypsinized 
and grown in a 24-well and finally to a 6-well format for Western blot analysis 
and also maintenance.  Altogether, three stable clonal cell lines per expression 
plasmid were verified and one clone was chosen for subsequent experiments.  
The stable cell lines were grown and maintained in complete DMEM 








2.6   Protein cell lysis 
Cells were washed twice with ice-cold DPBS and placed on ice for 15 min in 
125 µl of lysis buffer (containing 2 mM EDTA, pH 7.5; 100 mM NaCl, 10 
mM Tris HCl, pH 7.5; 0.5 % w/v deoxycholate; 1 % v/v triton X-100; 10 mM 
MgCl2; 1 µg/ml aprotinin; 100 µM Na3VO4; 1 mM PMSF).  The cells were 
scraped using a rubber policeman, collected in 1.5 ml eppendorf tubes, and 
centrifuged at 9,600 g for 10 min at 4 ⁰C.  The supernatants were collected and 
stored at -20 ⁰C until required. 
 
2.7   Lowry protein assay (BioRad protein assay kit) 
Samples were thawed on ice.  BSA standards (0.203 mg/ml, 0.405 mg/ml, 
0.675 mg/ml, 0.810 mg/ml, 1.010 mg/ml and 1.350 mg/ml) were prepared.  5 
µl of each BSA standard and sample was pipetted into 96-well plate in 
duplicate.  25 µl of solution A (Bio-Rad Laboratories, USA) was added into 
each well, followed by 200 µl of reagent B (Bio-Rad Laboratories, USA).  The 
samples were incubated in the dark at room temperature for 15 min.  
Absorbance was measured at 750 nm using i-control software on Tecan 
microplate reader (Tecan, Switzerland).  Protein concentration was determined 
from the BSA standard curve generated. 
 
2.8   Western blot analysis 
Western blot against phosphorylated Akt (pAkt), phosphorylated ERK1/2 
(pERK1/2) and phosphorylated STAT3 (pSTAT3) were performed in cells 




lysed 5 min after EGF stimulation based on our time pilot experiments that 
showed a peak of the expression of these proteins at 5 min after EGF 
stimulation (data not shown).  Western blot against cyclin D1, phosphorylated 
Rb (pRb) and p21 were performed in cells lysed 20 h after EGF stimulation 
based on the incubation time from previous studies determined by us and 
others (Fernandes et al., 2004; Tran and Stewart, 2003).  Western blot against 
caspase 3 was performed in cells lysed 72 h after EGF stimulation based on 
cell counting experiment.   
Total proteins (10-12 µg) were separated electrophoretically on 8 % or 12 % 
SDS-polyacrylamide gels and proteins were transferred onto polyvinyl 
difluoride (PVDF) membranes (Bio-Rad Laboratories, USA) for Western 
blotting.  Membranes were blocked with 5 % w/v skim milk in TBS-T 0.1 %, 
followed by overnight incubation with primary antibodies (Table 2.1) at 4 ⁰C.  
Subsequently, the membranes were incubated with secondary horseradish 
peroxidase (HRP)-conjugated antibodies (Table 2.1) at room temperature for 
1 h.  The protein bands were visualized by enhanced chemiluminescence (ECL, 
Amerdsham, UK).  Band intensities were scanned and quantified by utilising 
EPSON Perfection V200 PHOTO and TotalLab software (Nonlinear 
Dynamics, UK).  β-actin or GAPDH was used to normalize for equal loading 
of the samples.   
 
 




Table 2.1   Details of antibodies used in Western blot analysis 
Antibody Source Dilution 
Dilution buffer 
(in TBS-T 0.1 %) 
Company 
Primary antibodies 
CD151* Mouse 1:1000 1 % skim milk Serotec 
β-actin Mouse 1:15000 1 % skim milk Sigma 
GAPDH Mouse 1:1000 1 % skim milk Santa Cruz 
Caspase 3 Rabbit 1:1000 5 % skim milk Cell Signaling 
Cyclin D1 Rabbit 1:1000 5 % BSA Cell Signaling 
pRb (S780) Rabbit 1:1000 5 % BSA Cell Signaling 
Rb Mouse 1:1000 5 % BSA Cell Signaling 
p21 Rabbit 1:1000 5 % BSA Cell Signaling 
pAkt (S473) Rabbit 1:1000 5 % BSA Cell Signaling 
Akt Rabbit 1:1000 5 % BSA Cell Signaling 
pERK1/2 (T202/Y204) Mouse 1:1000 5 % BSA Cell Signaling 
ERK1/2 Rabbit 1:1000 5 % BSA Cell Signaling 
pSTAT3 (S727) Rabbit 1:1000 5 % BSA Cell Signaling 
EGFR Rabbit 1:1000 5 % BSA Cell Signaling 
KRAS Mouse 1:500 1 % skim milk Sigma 
 
Secondary antibodies (HRP-linked) 
anti-mouse IgG Horse 1:5000 5 % skim milk Cell Signaling 
anti-rabbit IgG Goat 1:2000 5 % skim milk Cell Signaling 
*Requires a non-reducing condition (without β-mercaptoethanol in sample 
buffer, refer to Section 2.1.13). 
 
2.8.1 Preparation of protein sample for Western blotting 
After the protein quantification by Lowry protein assay (refer to Section 2.7), 
protein samples (10 – 12 µg) was prepared for Western blotting.  3X sample 
loading buffer (half the volume of the protein samples) was added to each 
protein sample accordingly and boiled at 95 ⁰C for 4 min.  The samples were 
stored at -20 ⁰C before Western blot analysis was done. 
 




2.9   Cell counting by trypan blue exclusion 
Cell counting by trypan blue exclusion method was carried out as previously 
described (Tran and Stewart, 2003) after 72 h of EGF stimulation.  Briefly, 
cells were trypsinized, collected in 1.5 ml eppendorf tubes and centrifuged at 
13,800 g for 5 min.  Supernatants were discarded and pellets resuspended in 1 
ml of DPBS containing 2 % of FBS.  Trypan blue was used to identify non-
viable cells and the cells were counted using a hemocytometer.  Cell numbers 
were expressed as fold increment over basal. 
 
2.10   Mouse studies – Ovalbumin sensitization and challenge protocol 
C57BL/6J mice, aged 6 to 8 weeks, were purchased from The Jackson 
Laboratory (CD151 knockout, Jackson Laboratory, USA) and the Animal 
Resource Centre (wild-type, NUS, Singapore).  All procedures were approved 
by the Institutional Guidelines for Animal Care and Use Committee of NUS. 
Ovalbumin (OVA), the most commonly used allergen in small animal models 
(Matsumura, 1970), was used as the allergen in our study.  Mice were 
sensitized with 20 µg of OVA and 4 mg of aluminium hydroxide constituted 
in 0.1 ml of saline, by intraperitoneal (i.p.) injections, on days 0 and 14; and 
challenged with 1 % OVA aerosol, generated using an ultrasonic nebulizer 
(DeVilbiss Healthcare, Australia) for 30 min on days 22, 23 and 24.  Control 
mice received saline sensitization and / or saline challenge (S/S) using an 
identical protocol.  At 24 h after the last challenge, the lungs of the mice were 
collected, frozen in liquid nitrogen and stored at -80 ⁰C until required. 




A quarter of a frozen mouse lung lobe from each of the mouse lungs was 
homogenized in 500 µl of lysis buffer (refer to Section 2.1.6) using 
TissueLyser LT (Qiagen, USA). Determination of protein concentration and 
Western blotting analysis of mouse lung lysates was performed in the same 
manner as stated above. 
 
2.11   Immunohistochemistry 
Four-micron-thick tissue sections were deparaffinised in Neo-clear (Merck, 
Germany) and rehydrated in alcohol.  Antigen retrieval was carried out by 
either heating at 95-100 ⁰C for 10 min in Tris-EDTA pH 9.0 (for CD151 
staining) or incubating with proteinase K (Dako, Denmark) for 5 min at room 
temperature (for EGFR staining).  Sections were blocked with peroxidase 
blocking solution (Dako, Denmark) for 5 min at room temperature to reduce 
background given by endogenous peroxidases.  The sections were incubated 
with monoclonal mouse anti-human CD151 antibody (1:2000 dilution, 1 h) or 
mouse anti-human EGFR antibody (1:50 dilution, 30 min) (Dako, Denmark) at 
room temperature, followed by incubation with HRP-labelled goat dual anti-
mouse and anti-rabbit antibody (Dako, Denmark) for 30 min at room 
temperature.  Staining was developed with diaminobenzidine chromogen 
(DAB) (Dako, Denmark) for 10 min and sections were counterstained with 
Shandon Gill 3 hematoxylin (Thermo Scientific, UK).  The tissue sections 
were then dehydrated in alcohol, washed in Neo-clear, and mounted onto 
coverslips using histomount (National Diagnokstics, USA).   
 




2.11.1 NSCLC patient sample case selection 
Lung tumor tissues, in well-reserved paraffin-embedded blocks, from 20 early 
stage adenocarcinoma patients who underwent surgical resection were 
included in this study with patient consent (collaboration with Dr. Seet Ju Ee, 
National University Hospital, Singapore).  The EGFR mutation status was 
obtained by Sanger sequencing (Table 2.2).  This study was approved by the 
Institutional Review Board at the National University Health System in 
Singapore.  The stained tissues were examined and scored using a 4-tier 
scoring system using light microscopy.  The intensity of CD151 and EGFR 
expression was classified on an increasing scale of 0-3 by a pathologist, Dr. 
Seet Ju Ee, with “0” being undetectable and “3” being the most intensely 
stained. 
Table 2.2   Information of clinical samples 
Case number Block Research number EGFR mutation status 
NB13-164 B4 NUH1 Exon 18, 19 rare 
NB12-14082 A8 NUH2 Wildtype 
NB12-5216 A8 NUH3 Exon 21 
NB12-8608 A3 NUH4 Wildtype 
NB07-7381 A10 NUH5 Exon 19 
NB09-6855 A4 NUH6 Exon 21 rare 
NB11-13030 B3 NUH7 Wildtype 
NB12-12109 A5 NUH8 Wildtype 
NB10-8333 D3 NUH9 Exon 19 
NB13-918 B2 NUH10 Exon 18 rare 
NB09-9847 C7 NUH11 Wildtype 
NB11-24395 A3 NUH12 Exon 19 
NB11-1860 D1 NUH13 Exon 19 
NB10-23676 A3 NUH14 Exon 21 
NB12-6595 A2 NUH15 Wildtype 
NB10-18203 F6 NUH16 Wildtype 
NB10-16323 A3 NUH17 Wildtype 
NB10-15710 D7 NUH18 Exon 19 
NB12-9615 A6 NUH19 Wildtype 
NB13-6618 A8 NUH20 Wildtype 




2.12   Statistical analysis 
All results are expressed as mean + standard error of mean (mean + SEM) for 
at least 3 separate experiments.  Protein levels were expressed as fold 
increment over basal levels (for stimulation experiments) or EGF-stimulated 
controls (for cell number enumeration and signaling experiments).  All values 
were corrected against β-actin or GAPDH protein abundance.  Statistically 
significant differences were determined using one-way ANOVA with repeated 
measures, and followed by either (1) Dunnett’s post hoc multiple comparison 
test (for stimulation experiments) or (2) Bonferroni’s post hoc multiple 
comparison test (on selected pairs) (for cell number enumeration and signaling 
experiments).  A probability value of P < 0.05 was deemed significant.  
GraphPad Prism 6 software was used for statistical analysis.  
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Chapter 3: Results 
 
3.1   Factors upregulating CD151 expression are not receptor group-
specific 
To identify what factors are likely to contribute to CD151 overexpression in 
A549 cells, we stimulated the cells with different factors that are documented 
to be elevated in NSCLC, or are associated with the cancer progression.  
These factors include: growth factors that regulate receptor tyrosine kinase, 
pro-inflammatory cytokines and GPCR activators.  Three growth factors were 
used in this study, namely EGF, VEGF and TGF-β1.  As shown in Figure 
3.1A, 48 h stimulation with 10 ng/ml and 20 ng/ml of EGF increased CD151 
protein abundance significantly in A549 cells.  TGF-β1, at the concentrations 
of 1 ng/ml and 10 ng/ml, caused an increase of more than two folds in CD151 
protein level (Figure 3.1B).  Stimulation with VEGF, on the other hand, did 
not affect CD151 protein abundance even with a concentration as high as 100 
ng/ml (Figure 3.1C).  In terms of pro-inflammatory cytokines, 3 ng/ml and 10 
ng/ml of TNF-α upregulated CD151 protein expression significantly (Figure 
3.2A).  However, IL-1β did not increase CD151 protein abundance (Figure 
3.2B).  Both GPCR activators used in this study, histamine and nicotine, 
increased CD151 protein expression significantly (Figure 3.3).  10
-5
 M of 
histamine increased CD151 protein abundance by more than two folds (Figure 
3.3A) while 10
-6
 M of nicotine caused a 1.5 fold increase in CD151 protein 
abundance compared with the unstimulated cells (Figure 3.3B). 
 




3.2   EGF-induced upregulation of CD151 protein abundance is not 
cancer cell-type specific 
Given that EGFR is strongly linked with the poor prognosis of NSCLC, the 
ability of EGF to upregulate CD151 protein abundance has drawn our interest 
to focus on the role of CD151 in the growth factor property of EGFR.  We 
first wanted to determine whether EGF-induced upregulation of CD151 
expression that was observed in A549 cells was cancer cell-type specific.  We 
performed EGF stimulation in two other NSCLC cell lines, H358 and H1975, 
as well as a colon cancer cell line, SW620, and a breast cancer cell line, MDA-
MB-231.  As shown in Figure 3.4, EGF stimulation, at different 
concentrations, caused a significant increase in CD151 protein level not only 
in NSCLC cell lines (A and B), but also in colon and breast cancer cell lines 
(C and D). 
 
3.3   CD151 is required for EGF-induced increase in cell number 
EGF stimulates A549 cell proliferation (Croxtall et al., 1993).  We next 
determined whether EGF-induced CD151 expression was physiologically 
relevant by measuring cell proliferation as a functional output.   After 72 h 
stimulation with 10 ng/ml of EGF, a concentration which significantly 
upregulated CD151 protein abundance (Figure 3.1A), the A549 cell number 
was significantly higher as compared to the unstimulated cells (Figure 3.5).  
To determine whether CD151 was involved in this process, we used two 
different commercially available siRNAs that were directed against CD151 
(refer to Section 2.4).  CD151 was successfully knocked down by both CD151 




siRNAs transfected with two different siRNA transfection kits, as shown by 
the decrease in CD151 protein levels using Western blot analysis (Figure 
3.5A and B).  In the absence of EGF, the cell number of the CD151 
knockdown samples was observed to be similar to those of the controls, i.e. 
the untreated samples without any transfection, vehicle controls which were 
transfected with the transfection agents only, and the negative controls which 
were transfected with scrambled non-targeting siRNAs (Figure 3.5C and D).  
CD151 knockdown reduced the EGF-induced increase in cell number, 
maintaining the samples in low cell number comparable to the unstimulated 
samples (Figure 3.5C and D).  The results with siRNA#1 obtained from 
Dharmacon were confirmed with a second siRNA (#2, obtained from Qiagen), 
supporting the notion that CD151 is required for EGF-induced increase in cell 
number.   
 
Moreover, we show that a reduction in cell number with CD151 siRNA 
treatment was not due to siRNA-induced cell toxicity (as determined by trypan 
blue exclusion experiments; control = 1; CD151 siRNA = 0.67+0.41) or due to 
increased cell apoptosis, as measured by caspase 3 protein abundance – both 
EGF stimulation and CD151 knockdown did not have an effect on the caspase 
3 protein expression (Figure 3.6).  The activated form of caspase 3 could not 
be detected due to technical limitation with our experimental conditions.   
 
 




3.4   CD151 is sufficient to increase EGF-induced increase in cell number 
To corroborate our loss-of-function studies, we also performed gain-of-
function studies whereby stable A549 cell lines overexpressing CD151 and the 
empty vector were generated in our laboratory (refer to Section 2.5).  We first 
confirmed that the CD151-overexpressing cells were indeed overexpressing 
CD151 (carrying pEGFP-CD151 plasmid) by performing immunofluorescence 
imaging of GFP corresponding to the expression of CD151.  Figure 3.7A 
shows the expressions of GFP-tagged CD151 (pEGFP-CD151) and GFP-
tagged vector control (pEGFP-N3).  Notably, the membranous expression of 
pEGFP-CD151 in CD151-overexpressing cells was different from the nuclear 
and cytoplasmic localization of pEGFP-N3 observed in vector control cells.  
As a further confirmation by Western blot analysis, there was high CD151 
protein abundance in CD151-overexpressing cells versus vector control cells 
(Figure 3.7B).  Consistent with our siRNA results showing that CD151 is 
required for EGF-induced increase in cell number, we showed that CD151-
overexpressing cells were more sensitive to EGF stimulation as compared with 
vector control (Figure 3.7C).  The cell number of CD151-overexpressing cells, 
but not vector control cells, was significantly increased after 72 h of EGF 
stimulation (10 ng/ml). 
 
3.5   CD151 knockdown decreases EGF-induced phosphorylation of Akt 
and ERK1/2, but not STAT3 
We proceeded to investigate the signaling mechanism(s) behind CD151-
mediated increase in cell number induced by EGF.  We started by checking 




the activation status of three main downstream pathways of EGFR signaling, 
by measuring the abundance of the phosphorylated forms of Akt, ERK1/2 and 
STAT3.  EGF stimulation significantly increased the protein abundance of 
phosphorylated Akt (pAkt) and phosporylated ERK1/2 (pERK1/2) (Figure 
3.8A).  The phosphorylated STAT3 (pSTAT3) protein abundance was also 
higher with EGF stimulation although the difference was not statistically 
significant (Figure 3.8B).  CD151 knockdown did not affect the pAkt and 
pERK1/2 protein abundance at the basal level, but significantly reduced the 
EGF-induced phosphorylation of Akt and ERK1/2 proteins (Figure 3.8A).  
Interestingly, CD151 knockdown caused a slight increase in pSTAT3 protein 
abundance at the basal level, and significantly increased pSTAT3 protein 
abundance after EGF stimulation (Figure 3.8B). 
 
3.6   CD151 is sufficient to increase EGF-induced phosphorylation of Akt 
and ERK1/2, but not STAT3 
Gain-of-function studies on the activation status of Akt, ERK1/2 and STAT3 
proteins were then carried out using CD151-overexpressing cells and the 
vector control.  EGF-induced phosphorylation of Akt and ERK1/2 proteins 
were markedly increased in CD151-overexpressing cells compared with vector 
control cells (Figure 3.9A).  pSTAT3 protein abundance in CD151-
overexpressing cells, on the other hand, was significantly lower than the level 
in vector control cells, both in the unstimulated as well as EGF-stimulated 
samples (Figure 3.9B).  These observations support the results in the 




knockdown experiments, suggesting the role of CD151 in EGF-induced 
phosphorylation of Akt and ERK1/2 proteins. 
 
3.7   CD151 is required for EGF-induced cyclin D1 and phosphorylated 
retinoblastoma (pRb) protein abundance 
We further investigated the signaling mechanism by checking the expression 
level of cyclin D1, a nuclear protein which is required for the cell cycle 
progression in G1 phase (Baldin et al., 1993).  Interestingly, CD151 
knockdown increased cyclin D1 expression at basal level (without EGF 
stimulation) (Figure 3.10A).  As expected, EGF stimulation significantly 
increased cyclin D1 protein abundance in the control cells (Figure 3.10A).  
This was not observed when CD151 was knocked down.  We also examined 
the function of cyclin D1 by investigating the phosphorylation of the 
retinoblastoma (Rb) protein, a downstream target of cyclin D1.  Rb protein, in 
its hypophosphorylated active form, acts as a tumor suppressor by regulating 
cell cycle progression (Herwig and Strauss, 1997).  Cyclin D1 phosphorylates 
Rb, inhibiting its growth-inhibitory function, and causes cell cycle progression 
(Kitagawa et al., 1996).  Similar to the trends observed in cyclin D1 protein 
abundance (Figure 3.10A), phosporylated Rb (pRb) protein abundance was 
increased with CD151 knockdown at basal level (Figure 3.10B).  EGF 
stimulation significantly increased pRb protein abundance in the control, but 
not the CD151 knockdown cells. 
 




3.8   CD151 knockdown decreases p21 protein abundance 
We next determined the role of p21 in this process.  p21 functions as a 
regulator of cell cycle progression at the G1 and S phase by mediating p53-
dependent cell cycle arrest (el-Deiry et al., 1993).  As shown in Figure 3.11, 
p21 protein abundance was significantly decreased with CD151 knockdown.  
These observations were as expected given the opposite role of p21 protein to 
cyclin D1 and pRb proteins in cell cycle progression.  We also looked for p53 
protein expression but due to technical limitations, were not able to detect p53 
protein levels with our (two types) antibodies and experimental conditions. 
 
3.9   CD151 is required for the ovalbumin-induced activations of Akt and 
ERK1/2 in vivo 
Given the role of CD151 in mediating the activation status of Akt and ERK1/2 
proteins in vitro, we next examined whether similar effects were observed in 
an in vivo setting where these two proteins are observed to be elevated.  
Ovalbumin is a well characterized antigen used in in vivo models of allergic 
inflammation.  In these models, Akt and ERK1/2 have been shown to be 
elevated (Martins et al., 2010).  Consistent with this, ovalbumin challenge 
increased phosphorylation of Akt and ERK1/2 proteins in wildtype mice, as 
shown by the higher pAkt and pERK1/2 protein abundance in the ovalbumin 
sensitized and challenged wildtype mice (WT o/o) compared with the saline 
sensitized and challenged wildtype control (WT s/s) (Figure 3.12).  These 
were not observed in CD151 knockout mice.  Interestingly, CD151 protein 




abundance was also increased in WT o/o mice compared with WT s/s mice 
(Figure 3.12). 
 
3.10   CD151 was expressed and distributed in a more regulated manner 
in wildtype EGFR NSCLCs compared with mutated EGFR NSCLCs 
To examine the clinical relevance of our study, we investigated the 
relationship between EGFR and CD151 in NSCLC tissue samples using 
immunohistochemistry.  The representative images of the EGFR and CD151 
expressions with different staining scores (0-3) are shown in Figure 3.13 and 
Figure 3.14, respectively.  The twenty lung tumor tissues that were analyzed 
in this study were divided into two groups based on the EGFR status.  Ten of 
them contained wildtype EGFR (classified under wildtype EGFR group) while 
the remaining ten contained EGFR with some sorts of mutations (classified 
under mutated EGFR group) (refer to Table 2.2).  By comparison of intensity 
grading (determined by a pathologist, NUH), EGFR was expressed at a very 
low level in the tumor tissues with wildtype EGFR; the expression was 
undetectable in nine of the ten samples (grade 0), and was very low in the only 
sample that showed detectable staining (grade 1) (Figure 3.15A).  In contrast, 
among the ten samples in the EGFR mutated group, nine showed detectable 
EGFR expression, with five scored 1, two scored 2 and two scored 3 (Figure 
3.15A).  We next looked at the intensity grading for CD151 expression in the 
sample cohort.  In the wildtype EGFR group, CD151 staining was 
undetectable in one of the samples, seven of them were scored 1 and the 
remaining two were scored 2 (Figure 3.15B).  CD151 expression was 




observed in all the ten samples that belonged to the mutated EGFR group 
(Figure 3.15C).  Among the samples, eight were scored under the intensity 
grade 1, and one was scored under intensity grades 2 and 3 each. 
 
Both EGFR and CD151 proteins were not distributed evenly in the tumor 
tissue samples, with parts of the tissues showing positive staining while the 
rest not.  We investigated the distributions of EGFR and CD151 proteins in 
NSCLC by analyzing the percentage of the tumor tissues with positive 
staining for these two proteins (Figure 3.16).  The EGFR protein that was 
detected in the only EGFR wildtype tissue that showed positive EGFR 
staining was distributed in less than 10 % of the tumor (Figure 3.16A).  As 
compared to the limited distribution in the wildtype group, the distributions of 
EGFR protein in the mutated EGFR group varied from as low as no 
expression to as high as 90 % of the tumor.  In general, CD151 protein was 
distributed more widely than EGFR protein in EGFR wildtype group, with 
seven out of the ten showing a distribution in more than 70 % of the tumor 
cells (Figure 3.16B).  The CD151 protein distributions in the mutated EGFR 
group were much more complex.  Three of them showed much wider CD151 
protein distributions than EGFR protein, five showed similar area of 
distributions, while two showed a much lower percentage of tumor cells that 
were CD151 positive than EGFR positive (Figure 3.16C). 
 
 




3.11   CD151, EGFR and KRAS protein abundance in normal lung and 
lung cancer cell lines 
Finally, we measured the protein abundance of EGFR and CD151 to 
determine whether differences (correlation or inverse correlation) in 
expression level between these two proteins in different cell lines existed.  The 
cell properties of the different cell lines were tabulated in Table 3.1.  BEAS-
2B is a normal lung epithelial cell line while A549, H358, H1975 and SK-
MES-1 are NSCLC cell lines.  A549 and H358 are adenocarcinoma cell lines 
with wildtype EGFR and mutated KRAS, while H1975 is an adenocarcinoma 
cell line with mutated EGFR and wildtype KRAS.  SK-MES-1 is a squamous 
cell carcinoma cell line with wildtype EGFR and KRAS.  KRAS mutations 
were detected in more than 25 % of lung adenocarcinoma (Buttitta et al., 
2006).  Being a common mutation in NSCLC, we also measured KRAS 
expression in these cell lines.   
 
EGFR, KRAS and CD151 proteins were detected in all the cell lines with 
variable abundance (Figure 3.17).  No correlation between CD151 and EGFR 
protein abundance was observed.  Different from EGFR which showed similar 
expression levels in all the cell lines (Figure 3.17B and D), the lowest and 
highest protein abundance of CD151, similar to KRAS, was observed in 
H1975 cells and SK-MES-1 cells, respectively (Figure 3.17A, C and D).  
Comparing protein abundance in the cell lines, CD151 and EGFR protein 
abundance in other cell lines was not significantly different from A549 cells 




(Table 3.1).  H1975 cells had a significantly lower KRAS protein abundance 
than A549 cells (Table 3.1). 
 





Figure 3.1   EGF and TGF-β1, but not VEGF, upregulate CD151 protein 
abundance.  Grouped data and representative Western blots showing the 
effect of growth factors, (A) EGF, (B) TGF-β1 and (C) VEGF, on CD151 protein 
abundance.  Quiescent A549 cells were stimulated for 48 h with different 
concentrations of growth factors before protein analysis by Western blotting.  
Data are normalized to β-actin and expressed as fold increment over basal 
(unstimulated cells).  * P < 0.05, compared with basal, n=3-6. 





Figure 3.2   TNF-α, but not IL-1β, upregulate CD151 protein abundance.  
Grouped data and representative Western blots showing the effect of pro-
inflammatory cytokines, (A) TNF-α and (B) IL-1β, on CD151 protein 
abundance.  Quiescent A549 cells were stimulated for 48 h with different 
concentrations of pro-inflammatory cytokines before protein analysis by 
Western blotting.  Data are normalized to β-actin and expressed as fold 
increment over basal (unstimulated cells).  * P < 0.05, compared with basal, 
n=3.     
 
 





Figure 3.3   Histamine and nicotine upregulate CD151 protein abundance.   
Grouped data and representative Western blots showing the effect of GPCR 
activators, (A) histamine and (B) nicotine, on CD151 protein abundance.  
Quiescent A549 cells were stimulated for 48 h with different concentrations 
of GPCR activators before protein analysis by Western blotting.  Data are 
normalized to β-actin and expressed as fold increment over basal 
(unstimulated cells).  * P < 0.05, compared with basal, n=3-6.   





Figure 3.4   EGF-induced upregulation of CD151 protein abundance is not 
cancer cell-type specific.  Grouped data and representative Western blots 
showing the effect of EGF on CD151 protein abundance in (A) H358, (B) 
H1975, (C) SW620 and (D) MDA-MB-231 cells.  Quiescent cells were 
stimulated for 48 h with different concentrations of EGF.  Data are 
normalized to β-actin and expressed as fold increment over basal 
(unstimulated cells).  * P < 0.05, compared with basal, n=3-4.  
 





Figure 3.5   CD151 is required for EGF-induced increase in cell number.  
Quiescent A549 cells, with or without siRNA transfection using two different 
siRNA transfection kits (A,C: Dharmacon and B,D: Qiagen), were stimulated 
for 72 h with 10 ng/ml of EGF.  Knockdown of CD151 by siRNA (purchased 
from two different commercial companies) was confirmed by Western blot 
analysis (A,B).  Cells were counted using trypan blue exclusion to identify 
non-viable cells. Data are expressed as fold increment over EGF-stimulated 
controls.  * P < 0.05, compared with unstimulated  samples.  # P < 0.05, 
compared with EGF-stimulated controls.  untr: untreated samples (without 
transfection); trans ctrl: vehicle control (transfection reagent only); NT siRNA: 
non-targeting siRNA; n=3-6.  
 





Figure 3.6   Reduction in EGF-induced increase in cell number by CD151 siRNA 
is not due to caspase 3 activation.  Grouped data and representative Western 
blots showing the effect of CD151 knockdown on pro-caspase 3 protein 
abundance.  Quiescent A549 cells, with or without siRNA transfection, were 
stimulated for 72 h with 10 ng/ml of EGF.  Knockdown of CD151 by siRNA was 
confirmed by Western blot analysis.  Data are normalized to β-actin and 
expressed as fold increment over EGF-stimulated control.  ns: not significant; 
trans ctrl: vehicle control (transfection reagent only); n=4.  
 





Figure 3.7   CD151 is sufficient to increase EGF-induced increase in cell 
number.  (A) Immunofluorescence images and (B) representative Western 
blot showing confirmation of CD151 overexpression in cells overexpressing 
GFP-tagged CD151 (pEGFP-CD151) compared with control cells 
overexpressing the vector (pEGFP-N3).  (C) Grouped data showing the effect 
of CD151 overexpression on EGF-induced cell number.  Quiescent vector 
control or CD151-overexpressing cells were stimulated for 72 h with 10 ng/ml 
of EGF and counted using trypan blue exclusion to identify non-viable cells.  
Data are expressed as fold increment over EGF-stimulated vector control.  * P 
< 0.05, compared with unstimulated samples, n=5.  





Figure 3.8   CD151 knockdown decreases EGF-induced phosphorylation of Akt 
and ERK1/2, but not STAT3.  Grouped data and representative Western blots 
showing the effect of CD151 knockdown on EGF-induced phosphorylation of 
(A) Akt, ERK1/2 and (B) STAT3.  Quiescent A549 cells, with or without siRNA 
transfection, were stimulated for 5 min with 10 ng/ml of EGF.  Knockdown of 
CD151 was confirmed by Western blot analysis.  Data are normalized to (A) 
GAPDH or (B) β-actin and expressed as fold increment over EGF-stimulated 
controls.  * P < 0.05, compared with unstimulated  samples.  # P < 0.05, 
compared with EGF-stimulated controls.  trans ctrl: vehicle control 
(transfection reagent only); n=3-6.  
 
  





Figure 3.9   CD151 is sufficient to increase EGF-induced phosphorylation of 
Akt and ERK1/2, but not STAT3.  Grouped data and representative Western 
blots showing the effect of CD151 overexpression on EGF-induced 
phosphorylation of (A) Akt, ERK1/2 and (B) STAT3.  Quiescent vector control 
and CD151-overexpressing cells were stimulated for 5 min with 10 ng/ml of 
EGF.  CD151 overexpression in CD151-overexpressing cells was confirmed by 
Western blot analysis.  Data are normalized to (A) GAPDH or (B) β-actin and 
expressed as fold increment over EGF-stimulated vector control.  * P < 0.05, 
compared with unstimulated  samples.  # P < 0.05, compared with controls; 
n=3-4.  





Figure 3.10   CD151 knockdown inhibits EGF-induced cyclin D1 and 
phosphorylated retinoblastoma (pRb) protein abundance.  Grouped data and 
representative Western blots showing the effect of CD151 knockdown on 
EGF-induced cyclin D1 and pRb protein abundance.  Quiescent A549 cells, 
with or without siRNA transfection, were stimulated for 20 h with 10 ng/ml of 
EGF.  Knockdown of CD151 was confirmed by Western blot analysis.  Data are 
normalized to β-actin and expressed as fold increment over EGF-stimulated 
controls.  * P < 0.05, compared with unstimulated  samples.  # P < 0.05, 
compared with controls.  trans ctrl: vehicle control (transfection reagent 
only); n=3.  
 





Figure 3.11   CD151 knockdown decreases p21 protein abundance.  Grouped 
data and representative Western blots showing the effect of CD151 
knockdown on p21 protein abundance.  Quiescent A549 cells, with or without 
siRNA transfection, were stimulated for 20 h with 10 ng/ml of EGF.  
Knockdown of CD151 was confirmed by Western blot analysis.  Data are 
normalized to β-actin and expressed as fold increment over EGF-stimulated 
control.  # P < 0.05, compared with control.  trans ctrl: vehicle control 
(transfection reagent only); n=5.  
 






Figure 3.12   Ovalbumin challenge increases phosphorylation of Akt and 
ERK1/2 in wildtype mice but not in CD151 knockout mice.  Representative 
Western blots showing protein abundance of (A) phosphorylated Akt and (B) 
phosphorylated ERK1/2 in mouse lung lysates taken from ovalbumin / saline-
sensitized and challenged wildtype and CD151 knockout mice.  WT: wildtype 
mice; KO: CD151 knockout mice; s/s: saline sensitized / saline challenged; o/o: 









Figure 3.13   A 4-tier classification system to score the expression of EGFR.  
Immunohistochemistry staining of EGFR was carried out in clinical samples 
taken from NSCLC patients.  EGFR expression was tabulated using the 4-tier 
scoring system (0, 1, 2, 3), with “0” being undetectable and “3” being the 
most intensely stained.   (A) Score 0, (B), Score 1, (C) Score 2, (D) Score 3, (E) 
Isotype control.  





Figure 3.14   A 4-tier classification system to score the expression of CD151.  
Immunohistochemistry staining of CD151 was carried out in clinical samples 
taken from NSCLC patients.  CD151 expression was tabulated using the 4-tier 
scoring system (0, 1, 2, 3), with “0” being undetectable and “3” being the 
most intensely stained.   (A) Score 0, (B), Score 1, (C) Score 2, (D) Score 3, (E) 









Figure 3.15   Intensity grade comparison of EGFR and CD151 protein 
abundance in clinical samples taken from NSCLC patients with either wildtype 
or mutated EGFR.  (A) Scatter plot showing EGFR staining intensity in NSCLC 
with wildtype and mutated EGFR.  (B and C) Scatter plots showing CD151 
staining intensity with the corresponding wildtype (B) or mutated (C) EGFR 
staining intensity in the same sample.  Lung tumor tissue samples from NSCLC 
patients with wildtype or mutated EGFR were stained for EGFR and CD151.  
The expression intensities of EGFR and CD151 were scored 0-3, with “0” 
being undetectable and “3” being the most intensely stained.  Each color 
represents a patient sample, * P < 0.05, compared with samples with 
wildtype EGFR, n=10 per EGFR status. 
 





Figure 3.16   Percentage tumor cells grading comparison of EGFR and CD151 
protein distributions in clinical samples taken from NSCLC patients with 
either wildtype or mutated EGFR.  (A) Scatter plot showing percentage of 
tumor stained positive for EGFR in NSCLC with wildtype and mutated EGFR.  
(B and C) Scatter plots showing percentage of tumor stained positive for 
CD151 with the corresponding tumor percentage with positive wildtype (B) 
or mutated (C) EGFR staining in the same sample.  Lung tumor tissue samples 
from NSCLC patients with wildtype or mutated EGFR were stained for EGFR 
and CD151.  The distributions of EGFR and CD151 were expressed as 
percentage of tumor with positive staining for each protein.  Each color 
represents a patient sample, * P < 0.05, compared with samples with 
wildtype EGFR, n=10 per EGFR status.  
 





Figure 3.17   Comparison of CD151, EGFR and KRAS protein abundance in 
normal lung and lung cancer cell lines.  Grouped data (A-C) and 
representative Western blots (D) showing the protein abundance of (A) 
CD151, (B) EGFR and (C) KRAS in normal lung cell line, BEAS-2B, and lung 
cancer cell lines, H358, H1975 and SK-MES-1, compared with A549 cells.  Data 
are normalized to β-actin and expressed as fold increment over A549 cells.  # 
P < 0.05, compared with A549 cells, n=3.  
 
 
Table 3.1   Cell properties, and CD151, EGFR and KRAS protein abundance 
relative to A549 cells 
Cell line Normal / Cancer Mutation 
status 
Protein abundance 
(relative to A549 cells = 1) 
EGFR KRAS CD151 EGFR KRAS 
A549 Adenocarcinoma WT mut 1 1 1 
BEAS-2B Normal WT WT no Δ no Δ no Δ 
H358 Adenocarcinoma WT mut no Δ no Δ no Δ 
H1975 Adenocarcinoma mut WT no Δ no Δ ↓ 
SK-MES-1 Squamous cell 
carcinoma 
WT WT no Δ no Δ no Δ 
Abbreviations: WT, wildtype; mut, mutated; no Δ, no difference; ↓, 
significantly lower expression than that in A549 cells. 
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Chapter 4: Discussion 
 
CD151 is overexpressed in more than 25 % of NSCLCs and the high 
expression is correlated with reduced overall and disease-free survival (Kwon 
et al., 2013).  Despite the recognition of the clinical significance and 
contributions of CD151 in NSCLC, the fundamental question that remains 
largely unanswered is what factor(s) are likely to increase the expression of 
CD151.  Our study has demonstrated for the first time the upregulation of 
CD151 protein abundance in NSCLC by various factors (growth factors, pro-
inflammatory cytokines and G protein-coupled receptor activators).  In 
particular, we show that EGF significantly increased CD151 expression and 
went further on to determine the functional importance of this association in a 
cell culture model. We show that CD151 mediates EGF-induced NSCLC cell 
proliferation, possibly via the Akt and ERK1/2 pathways, with a feedback 
inhibitory effect by STAT3.  In addition, our study with clinical samples 
suggests a regulatory role between EGFR and CD151 in NSCLC; as well as a 
possible correlation between CD151 and KRAS in NSCLCs with wildtype 
EGFR.   
 
The finding that various factors, ranging from growth factors, pro-
inflammatory cytokines, to GPCR activators, could cause CD151 
overexpression in cancer is a novel one.  Notably, these factors were neither 
limited to a specific family of proteins, nor involving all the members of a 
specific family (Figure 3.1 – 3.3).  This is not surprising due to a few reasons: 




(1) regulation of CD151 protein expression may occur at a point downstream 
of the factor-activated signaling pathways which is common among different 
families of proteins; (2) the signaling pathways activated by different factors 
are not identical even if they belong to the same family, and (3) crosstalk 
between different factors and / or different pathways can lead to different 
physiological outcome.  It is important to note that the positive regulators of 
CD151 are not limited to the ones that showed significance in upregulating 
CD151 protein abundance in our study.  Combinations of different factors, 
including those that alone, do not show significance in our study, may show 
additive, synergistic or even antagonistic effect.  These permutations and 
combinations will be explored further in our future studies.  Prior to our 
studies, a negative regulator of CD151 expression was identified.  Hypoxia 
inducible factor-1-alpha (HIF-1α) suppresses CD151 expression in hypoxia 
(Chien et al., 2008).  Inversely, the effect of an increase oxygen tension on 
CD151 expression remains to be further explored.  
 
Growth factor receptors are a major group of tetraspanin-interacting proteins 
(Table 1.1).  For example, CD9 interacts with heparin-binding EGF-like 
growth factor (HB-EGF) to upregulate its activity (Lagaudriere-Gesbert et al., 
1997); while CD82 interacts with c-Met to reduce its activation signal by 
inhibiting its crosstalk with integrins (Sridhar and Miranti, 2006; Todeschini et 
al., 2007).  In addition, CD82 has been shown to directly bind to EGFR to 
suppress EGF-induced lamellipodial extensions and cell migration by 
regulating compartmentalization and ligand-induced dimerization of EGFR 
(Odintsova et al., 2000; Odintsova et al., 2003).  It helps activated EGFR to 




switch from confined to random diffusion, thereby mediating EGFR cell-
surface dynamics and signaling (Danglot et al., 2010).  We show for the first 
time that EGF is able to not only upregulate CD151 protein expression in 
NSCLC cells but also in breast and colon cancer cells (Figure 3.1A, 3.4). 
Moreover, EGF-induced NSCLC cell proliferation was CD151-dependent.  
CD151 knockdown did not affect A549 cell number basally, but decreased the 
cell proliferation induced by EGF (Figure 3.5).  Similar observations have 
previously been reported by Franco and colleagues who showed that CD151 
controls HGF-induced A549 cell proliferation by regulating ERK1/2, without 
affecting the basal cell proliferation (Franco et al., 2010).  Consistent with 
their findings, a decrease in EGF-induced phosphorylation of ERK1/2, and 
also Akt, was observed when CD151 was knocked down in our study (Figure 
3.8A), suggesting the possible involvement of these two proteins in CD151-
mediated cell proliferation induced by EGF.  CD151 also promotes breast 
cancer cell proliferation induced by TGF-β1 via its involvement in regulating 
the compartmentalization of TGF-β type 1 receptor and controlling TGF-β1-
induced p38 activation (Sadej et al., 2010).  In support of this, we also show 
that TGF- β1 is able to upregulate CD151 protein abundance (Figure 3.1B), 
however we have yet to determine whether this process also involves p38 
activation. 
 
Prior to our current study, there has been no report of a direct association 
between CD151 expression induced by EGFR.  There are however, a handful 
of studies that have linked CD151 with EGFR signaling.  CD151 collaborates 
with laminin-binding integrins and EGFR receptors to drive mammary tumor 




onset, survival and metastasis (Deng et al., 2012).  Using mammary cell lines, 
Yang and colleagues showed that CD151 affects integrin-dependent cell 
morphology, migration, invasion, adhesion, signaling and EGFR crosstalk by 
determining the molecular organization of laminin-binding integrins on the 
cell surface (Yang et al., 2008).  In the same study, however, EGF-induced 
cell proliferation and survival are not impaired in CD151-silenced cells, 
contradicting the findings in our study.  Another study shows that CD151 
depletion did not affect the proliferation of MDA-MB-231 breast cancer cell 
line in three-dimensional ECM, even with the presence of EGF (Sadej et al., 
2009), demonstrating a lack of association between EGF and CD151 functions.  
Though we show that EGF can also induce CD151 protein expression in 
MDA-MB-231 cells, we did not explore further the role of CD151 in these 
cells.  Thus, the contradicting results may be due to the different cancer 
models being investigated (breast versus NSCLC), as well as the difference in 
experimental settings between the studies (e.g. three-dimensional ECM versus 
plastic). 
 
In terms of signaling, a number of studies have demonstrated the role of 
CD151 in Akt and ERK1/2 activation.  Consistent with our results, depletion 
in CD151 has been reported to be accompanied by decreased EGF-induced 
ERK1/2 phosphorylation, while CD151 overexpression increases ERK1/2 
phosphorylation (Deng et al., 2012; Yang et al., 2012; Zuo et al., 2010).  
CD151-induced endothelial cell proliferation is mediated by Akt activation 
(Zheng and Liu, 2007).  In contrast, there are studies that showed diminished 
Akt but unaltered ERK1/2 phosphorylation (Takeda et al., 2007); diminished 




ERK1/2 but unaltered Akt phosphorylation (Deng et al., 2012); and unaltered 
phosphorylation of both Akt and ERK1/2 (Sadej et al., 2009) with CD151 
depletion.  Besides mediating proliferation in NSCLC cells as shown in our 
study, CD151 promotes mammary epithelial cell proliferation, hepatocellular 
carcinoma cell proliferation, skin squamous cell carcinoma tumor proliferation 
and esophageal cell carcinoma tumor proliferation (Fei et al., 2012; Li et al., 
2013; Novitskaya et al., 2010; Suzuki et al., 2011).  In addition to Akt and 
ERK1/2, other signaling molecules involved in these studies include PKC, 
STAT3, Rac and Cdc42.  Endothelial cell proliferation has also been shown to 
be CD151-dependent.  CD151 promotes proliferation in human umbilical vein 
endothelial cells (HUVECs), possibly via PI3/Akt and ERK1/2 pathways; and 
bovine aortic endothelial cells (BAECs), possibly via FAK, ERK, 
PI3K/Akt/eNOS and Rac/Cdc42 signaling pathways (Liu et al., 2011; Peng et 
al., 2013). 
 
Importantly, we also show in vivo that the phosphorylation of Akt and ERK1/2 
induced by ovalbumin exposure was accompanied by an increase in CD151 
protein abundance.  Moreover, the phophorylation of both Akt and ERK1/2 
was impaired in CD151 knockout mice compared with the wildtype mice that 
were exposed to ovalbumin (Figure 3.12).  Although these findings were 
observed using an allergen-induced inflammatory mouse model, the results 
may be translated to cancer given the critical roles of inflammation in cancer.  
In addition to the fact that many cancers arise from sites of chronic 
inflammation, inflammation plays important role in neoplastic progression, 
with inflammatory cells being the most critical players in tumor 




microenvironment (Coussens and Werb, 2002).  Consistent with this, we show 
that pro-inflammatory cytokine, TNF-αcan upregulate CD151 protein 
abundance in vitro (Fig 3.2A). 
 
STAT3 is known to promote cell cycle progression and cellular transformation, 
and to prevent apoptosis (Bromberg and Darnell, 2000).  It was surprising to 
see a significant increase in pSTAT3 protein abundance despite the decreased 
cell number in CD151 knockdown samples stimulated with EGF (Figure 3.8).  
Moreover, exogenous CD151 protein was sufficient to decrease pSTAT3 
protein abundance, not only at the basal level, but also in the presence of EGF 
(Figure 3.9).  Being an important downstream protein of EGFR signaling, the 
unchanged level of pSTAT3 after EGF stimulation was also unexpected.  
Given the ability of cancer cells to sustain proliferative signaling as one of the 
hallmarks of cancer (Hanahan and Weinberg, 2011), the increase in pSTAT3 
protein abundance upon CD151 knockdown might be due to the cells’ attempt 
to sustain proliferation when Akt and ERK1/2 pathways were disrupted.  This 
kind of feedback inhibition is frequently seen when targeting a selected 
molecule as many of the signaling pathways are interconnected to maintain 
homeostasis.  For example, mTOR inhibition induces insulin receptor 
substrate-1 expression and activates Akt; Akt inhibition induces a set of 
receptor tyrosine kinases such as HER3, insulin-like growth factor-1 receptor 
(IGF-1R) and insulin receptor (Chandarlapaty et al., 2011; O'Reilly et al., 
2006).   
 




Interestingly, despite the observation that basal cell number was unchanged 
with CD151 knockdown, cyclin D1 and pRb protein abundance was increased 
while p21 protein abundance was decreased (Figure 3.10, 3.11).  We reason 
that CD151 may be influencing cell cycle arrest post S phase or at G2/M phase 
and the thinking logic behind this is as follows.  Cyclin D1 expression 
oscillates moderately throughout the cell cycle, with the maximum expression 
level in G phase (Semczuk and Jakowicki, 2004).  It serves as a key integrator 
in early to mid-G1 phase, promoting cell proliferation by regulating the cell 
cycle progression (Fu et al., 2004).  Rb, in its inactive hypophosphorylated 
form, binds to E2F transcription factors to repress cell cycle progression 
(Weinberg, 1995).  In G1 phase, cyclin D1 phosphorylates Rb to activate E2F 
transcription factors, allowing the cells to proceed from G1 to S phase for 
proliferation (Bartek and Lukas, 2001).  p21 protein is a p53-inducible cell 
cycle inhibitor that blocks cyclin D1 function to inhibit cell cycle progression 
in the G1-S transition (el-Deiry et al., 1994).  The expression of cyclin D1, 
pRb and p21 protein observed in this study might be a result of feedback 
inhibition by STAT3 signaling.  Besides activating cyclin D1 protein in cell 
cycle, STAT3 recruits cyclin D1 to the promoter of p21 to inhibit its 
expression (Bienvenu et al., 2005).  Both Akt and ERK1/2 have been reported 
to regulate G2/M phase transition in cell cycle.  Activation of Akt has been 
shown to overcome DNA damage-induced G2/M cell cycle checkpoint 
(Kandel et al., 2002).  C-C chemokine receptor 7 promotes NSCLC cell 
proliferation by upregulating cyclin A, cyclin B1 and cyclin-dependent kinase 
1 (CDK1) proteins which are related to G2/M phase transition, without 
affecting the expression of cyclin D1 and cyclin E (Xu et al., 2011).  The 




decreased activation of Akt and ERK1/2 upon CD151 knockdown may inhibit 
cell proliferation by inducing cell cycle arrest at G2/M phase or inhibiting / 
delaying cells from transiting to G2/M phase.  Future experiments such as cell 
cycle analysis by flow cytometry and detection of regulatory proteins in G2/M 
phase by Western blotting would be useful to confirm this.  Moreover, it 
appears that unless stimulated by EGF, CD151 alone is able to maintain cells 
at a steady state such that the protein expression of cyclin D1 and pRb are kept 
under control. 
 
Our findings about the role of CD151 in EGF-induced proliferation in A549 
cells are summarized in Figure 4.1.  EGF upregulates CD151 protein 
abundance.  CD151 positively regulates EGF-induced activation of Akt and 
ERK1/2 while inhibits activation of STAT3.  In the absence of EGF, CD151 
inhibits STAT3 signaling to maintain low expression levels of cyclin D1 and 
pRb, which in turn increase p21. With EGF stimulation, the STAT3-mediated 
alteration in cyclin D1, pRb and p21 protein abundance is not observed, 
possibly hindered by the decreased Akt and ERK1/2 signaling.  The 
mechanism by which CD151 mediates EGF-induced A549 cell proliferation is 
at the level of Akt and ERK1/2 in the G2/M phase of the cell cycle.   
 





Figure 4.1   Propose mechanism by which CD151 may regulate EGF-induced 
A549 cell proliferation (Dashed lines).  Solid lines indicate current accepted 
mechanism by which EGF induces cell proliferation.  Abbreviation: EGF, 
epidermal growth factor; EGFR, epidermal growth factor receptor; ERK1/2, 
extracellular signal-regulated kinase 1/2; STAT3, signal transducer and 
activator 3; pRb, phosphorylated retinoblastoma.  
 




There are a few limitations in our study: (1) The in vitro experiments were 
carried out in cell lines.  The use of primary cancer cells in future would 
further increase the significance of this study.  (2) Not all the concentrations at 
which the factors significantly upregulated CD151 protein abundance tally 
with the serum level of the factors detected in cancer patients.  For example, 
although we show that 3 ng/ml of TNF-α significantly increased CD151 
protein abundance (Figure 3.2A), the serum levels of TNF-α in NSCLC 
patients and healthy controls are at pg/ml (Song et al., 2013).  Also, the 
median serum level of EGF in NSCLC patients is around 200-250 pg/ml 
(Kasahara et al., 2010).  However, 10 ng/ml of EGF that was used in our study 
is commonly accepted in literature for various other functional outputs (Deng 
et al., 2012; Yang et al., 2008).  Nonetheless, the difference between the 
cellular response and physiological response to stimulants may exist, 
contributing to inconsistencies in the effective concentrations.  (3) Although in 
vivo study demonstrating the role of CD151 in allergen-induced Akt and 
ERK1/2 activation was carried out, the effect with EGF stimulation remains to 
be explored. 
 
Clinically, surgical resection is the most effective treatment for early stage 
NSCLC patients whose tumors are confined to the primary site and who have 
no or minimal lymph node involvement (Cheng et al., 2011).  For patients 
with advanced or recurrent NSCLC, platinum-based chemotherapy, such as 
cisplatin and paclitaxel, is the mainstay of treatment but the results of 
treatment are not encouraging with modest efficacy and significant toxicity 
(Carney, 2002; Schiller et al., 2002).  In recent years, the management of lung 




cancer has been shifted toward molecular-guided, individualized treatment 
with the improved understanding of the molecular biology of the disease.  For 
instance, EGFR TKIs have demonstrated significantly improved responses and 
outcomes in advanced NSCLC patients, not only as the first-, second- or third-
line therapy, but also as maintenance treatment (Cappuzzo et al., 2010; Mok et 
al., 2009a; Shepherd et al., 2005).  Somatic EGFR mutations are sensitive and 
specific predictive biomarkers for response to TKIs in NSCLC (Dahabreh et 
al., 2010).  The use of EGFR gene copy number and protein expression in 
predicting patient response to TKI treatments is not conclusive (Cheng et al., 
2011; Dahabreh et al., 2010).  We show that high EGFR protein expression in 
NSCLC tumor was correlated with EGFR mutations (Figure 3.15A).  This is 
consistent with the results from previous studies (El-Zammar et al., 2009; 
Liang et al., 2010).   
 
Contradicting results have been reported regarding the association between 
EGFR and CD151 protein expression in tumors.  Romanska and colleagues 
who analyzed protein distributions in 83 oral squamous cell carcinoma 
samples reported that tumors positive for CD151 were usually also positive for 
EGFR, and that this association was only observed in tumor mass, but not the 
invasive front of the tumor samples (Romanska et al., 2013).  However, no 
association between EGFR and CD151 expression was found in invasive 
breast cancer (Kwon et al., 2012).  Our study is the first study investigating the 
association between EGFR and CD151 protein expressions in NSCLC.  We 
found no correlation between EGFR and CD151 protein expressions in both 
NSCLCs with wildtype and mutated EGFR (Figure 3.15B and C).  In vitro 




study comparing the EGFR and CD151 protein expressions in different cell 
lines also demonstrated a lack of association between these two proteins 
(Figure 3.17).  Of note, this lack of association might be due to the lack of 
power in the study, given the limited number of clinical samples being 
analyzed.  It would be interesting to know whether there is a correlation 
between CD151 and different EGFR mutations too.  Although we had 
information about the kinds of mutations in the samples from EGFR mutated 
group (Table 2.2), the maximum number of samples in one specific mutation 
was only five (exon 19 mutation); therefore no association could be 
determined.  Our study was also constrained with the lack of information 
about the clinical background of the patients such as age, gender and smoking 
status.  Future studies involving a larger sample size with background patient 
history would be useful in obtaining more meaningful results. 
 
Studies have shown that NSCLC patients with wildtype and mutated EGFR 
responded differently to EGFR TKI treatment.  For instance, patients with an 
EGFR mutation had much higher response rates and longer progression free 
survival than those with wildtype EGFR when treated with an EGFR TKI, 
gefitinib (Sequist et al., 2008).  Among the NSCLCs with wildtype EGFR in 
our study, CD151 protein expressions were consistently higher as compared 
with EGFR protein expressions which were very low (Figure 3.15B).  Most of 
the samples analyzed exhibited a wide distribution of CD151 proteins (Figure 
3.16B).  These trends were not observed in NSCLCs with EGFR mutations, in 
which both the expression and distribution of CD151 protein were more 
complex (Figure 3.15C and Figure 3.16C).  Interestingly, we show in our 




stimulation study that a high concentration of EGF at 100 ng/ml was required 
to cause a significant increase in CD151 protein abundance in H1975 cell line 
that harbors mutated EGFR (Figure 3.4B), while lower concentrations at 1 
ng/ml and 10 ng/ml were sufficient to significantly upregulate CD151 protein 
in wildtype EGFR NSCLC cell lines, H358 and A549 (Figure 3.4A and 
Figure 3.1A).  All together, these observations support a role of EGFR in 
regulating CD151 protein or CD151 in EGFR regulation.   
 
Despite the small sample size in this study, it appears that there is a subset of 
NSCLCs with a wide distribution of CD151 protein in the wildtype EGFR 
group (Figure 3.16B).  Whether this subset of NSCLCs was correlated with 
the activating pathways in wildtype EGFR tumors, such as KRAS mutations, 
anaplastic lymphoma kinase (ALK) gene rearrangements, BRAF mutations 
and MET gene amplification (Hirsch et al., 2013), was undetermined due to 
the lack of the mutation information.  Nonetheless, a trend towards the 
correlation between CD151 and KRAS protein levels was observed in vitro 
(Figure 3.17), suggesting a new direction of investigating CD151 proteins.  
Future studies involving CD151 and KRAS proteins may help to better our 
understanding of CD151 contributions in NSCLC. 
 
Importantly, our findings in NSCLC cells may be applied to other cancers 
with CD151 overexpression as EGF was found to consistently upregulate 
CD151 protein abundance in colon and breast cancer cell lines (Figure 3.4).  
Consistent with this, Sala-Valdes and colleagues have reviewed the 




importance of tetraspanins in tumorigenesis and cancer progressing, 
suggesting targeting tetraspanins as a promising cancer therapy (Sala-Valdes 
et al., 2012).  The regulatory effect of CD151 on ErbB2 drug sensitivity has 
been demonstrated; the resistance to anti-ErbB2 agents develops when 
ErbB2+ breast cancer cells use CD151-integrins complexes to engage laminin-
5.  Targeting CD151 markedly enhances sensitivity to ErbB2-targeted drugs 
(Yang et al., 2010).  The observation of STAT3 activation upon CD151 
knockdown suggests a better therapeutic effect with combinatory therapy 
targeting both these proteins. 
 
In conclusion, our study has demonstrated for the first time the upregulation of 
CD151 protein abundance in NSCLC by various factors.  CD151 mediates 
EGF-induced NSCLC cell proliferation, possibly via the Akt and ERK1/2 
pathways, with a feedback inhibitory effect by STAT3.  In addition, our study 
with clinical samples suggests a regulatory role between EGFR and CD151 in 
NSCLC; as well as a possible correlation between CD151 and KRAS in 
NSCLCs with wildtype EGFR.  These findings provide a basis for future work 
to develop novel approaches for targeting CD151 in the treatment of NSCLC, 
as well as other cancers with CD151 overexpression. 
 





Other future works that could be carried out following our study include: (1) 
dissecting the mechanisms in which the different factors upregulate CD151 in 
order to decipher whether there is a common converging signaling molecule 
that could link up all the different factors; (2) the significance of nicotine in 
lung cancer has been described in Section 1.4.2 (page 17).  The finding that 
nicotine can increase CD151 protein abundance suggests a possible role of 
CD151 in nicotine-related lung cancer.  Future investigation on this would be 
helpful; (3) exploring the role of CD151 in tumor progression induced by 
other factors, such as TGF-β1 and TNF-α, that are shown to upregulate CD151 
protein abundance; (4) determining the role of CD151 in other EGF-induced 
functions such as migration and invasion; (5) investigating the possible 
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